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Chemical substances and drugs
CTOP: D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2
DAMGO: [D-Ala2,N-Me-Phe4,Gly5-ollenkephalin
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MX: Pertussis toxin
Buffers
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Receptors
PAR: Protease-activated receptor
PDGFRct: PDGF ct receptor
PDGFRP: PDGF P receptor
Endogenous substances
BDNF: Brain-derived neurotrophic factor
PDGF: Platelet-derived growth factor
POMC: Proopiomelanocortin
Enzymes and intracellular messengers
ERK: Extracellular signal regulated kinase
PKA: Protein kinase A
PKC: Protein kinase C
PLC: Phospholipase C
p-cPKC: Phosphorylated-conventional PKC
PTK: Protein tyrosine kinase
TH: Tyrosine hydroxylase
p-TH: Phosphorylated-TH
Brain region
ACC: Anterior cingluate cortex
CG: Cingulate cortex
N.Acc.: Nucleus accumbens
SI: Primary somatosensory area
SII: Secondary somatosensory area
VTA: Ventral tegmental area
Injection route
i.t.: Intrathecal
s.c.: Subcutaneous
Imstrument
CPP: Conditioned place preference
ECD: Electrochemical detection
HPLC: High-performance liquid chromatography
fMRI: Functional magnetic resonance imaging
PET: Positron emission tomographic
RT-PCR: Reverse transcription-polymerase chain reaction
SPET: Singl photon emission tomographic
Others
ANOVA: Analysis of variance
BOLD: Blood oxygen level-dependent
rCBF: Regional cerebral blood flow
CNS: Central nervous system
CSF: Cerebro spinal fluid
DRG: Dorsal root ganglion
IR: Immunoreactivity
NIH: National Institute of Health
NeuN: Neuronal nuclei
ROIs: Regions of interest
S.E.M.: Standard error mean
Ser: Serine
wnO: World Health Organization
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General Introduction
Neuropathic pain
   Neuropathic pain, which is characterized by spontaneous burning pain, hyperalgesia
(exaggerated pain in response to painful stimuli) and allodynia (pain caused by
normally innocuous stimuli), is the most difficult pain to manage in the pain clinic.
Since general analgesics such as non-steroidal anti-inflammatory drugs and opioids
often fail to improve neuropathic pain, it is widely accepted that complicated
mechanisms may underlie this pain syndrome. A growing body of evidence suggests
that sensory nociceptive processing in the spinal dorsal horn appears to undergo
significant plastic changes following peripheral nerve injury, leading to the
development of neuropathic pain '). To date, although many studies have focused on
the }ong-term changes in the functions of spinal cord dorsal horn neurons after nerve
injury, the mechanisms of the development and maintenance of neuropathic pain are
still not well understood.
Brain-derived neurotrophic factor/Platelet-derived growth factor
   A considerable amount of evidence suuports the notion that neurotrophins may be
involyed jn the modulation of synaptic pJasticity. It is well known that
immunostaining for another neurotrophin, brain-derived neurotrophic factor (BDNF),
which is normally synthesized in small- to medium-diameter sensory dorsal root ganglia
(DRG) neurons, and the level of BDNF mRNA are increased in ipsilateral DRGs
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following sciatic nerve lesion 23). In addition, the available evidence to date suggests
that BDNF may be released from primary afferent neurons in an activity-dependent
manner as an endogenous neurotransmitter/ neuromodulator 47).
   Platelet-derived growth factor (PDGI), which is a neurotrophin, is a major mitogen
for fibroblasts, smooth muscle cells and other cells 8'9). It is a dimeric molecule that
consists of disulfide-bonded, structurally similar A- and B-polypeptide chains, which
combine to form homo- and heterodimers 'O). The PDGF isoforms exert their cellular
effects by binding to and activating two structurally related protein thyrosin kinase
receptors, denoted the ct-receptor and the 6-receptor "-'3). The activation of PDGF
receptors leads to the stimulation of cell growth, but also to changes in cell shape and
motility: PDGF induces reorganization of the actin filament system and stimulates
chemotaxis, i.e., a directed cell movement toward a gradient of PDGF '`'D.
   Recent studies have demonstrated that PDGF A-chain mRNA is found in neurons in
spinal cord and dorsal root ganglia of both embryoa and adult animals i8). PDGF
B-chain protein is also found in neurons in several central nervus system (CNS) regions
in both the embryo and adult '9). Considering these findings, I can speculate that
PDGF within the spinal cord plays an important role in various critical physiological
responses including pain perception. Thus, it is worthwhile to investigate the role of
PDGF as well as BDNF in the modulation of synaptic plasticity linked to chronic pain.
Protein ldnase C
2
   Several protein kinases, such as protein kinase A (PKA) and protein kinase C (PKC),
phosphorylate their target proteins, leading to transcriptional and/or posttranslational
changes which in turn produce various critical physiological responses including pain
perception i'20). In addition, several lines of evidence have demonstrated that activated
protein kinases play a key role in the modulation of synaptic plasticity 2'-23).
   PKC, which is activated by 1,2-diacylglycerol in the presence of Ca2' and
phospholipids, acts as a key enzyme for signal transduction in various physiological
processes 20'2'2`). The protein phosphorylation catalyzed by PKC may strongly
modulate various processes, such as the release of neurotransmitters, cell proliferation
and differentiation, and potentiation and desensitization of several kinds of receptor
systems 20'2i'24). Recent studies have revealed a family of closely related proteins that
can be subdivided on the basis of certain structural and biochemical similarities:
Ca2'-dependent or conventional isoforms (PKCct, PI, PII and y; cPKCs),
Ca2"-independent or novel isoforms (PKC6, E, n and e; nPKCs), and atypical isoforms
(PKCX and ig; aPKCs) 22•").
   PKCct, PI, PII, y, E 6 and ig jsoforms have been identified jn the brain and spinal
cord. These various isoforms appear to be differentially distributed in the mammalian
central nervous system, and show cell type- and cellular component-specificity 25'26).
Interestingly, phorbol 12,13-dibutyrate (PDBu), a specific PKC activator, when given
intrathecally (i.t.), produced spontaneous nociceptive pain-like behavior and
long-lasting thermal hyperalgesia associated with an enhancement of neuronal activity
in some brain regions related to pain perception 27'28). Thus, the activation of protein
                                   3
kinases may be responsible for the production of central sensitization, the spread of pain
sensitivity to areas outside of tissue injury and the development of pain in response to
low-intensity stimuli 20•as•26).
   Among these PKC isoforms, it has been reported that PKCy--Iike immunoreactivity
was clearly increased in the dorsal horn of the rat spinal cord following peripheral nerve
injury 29). Furthermore, a neuropathic pain-like state induced by nerve ligation was not
caused in mice that lacked the PKCy gene 303'). These findings strongly suggest that
activated PKC in the spinal cord may result in central sensitization to nociceptive
transmission, which leads to the development of neuropathic pain.
Pain ascending pathway
   The primary afferent nociceptor is generally the initial structure involved in
nociceptive processes. The primary afferent fibers associated with the transmission of
nociceptive signals to the substantia gelatinosa in the dorsal horn can be grouped into
two main categories: small myelinated (A-6) and unmyelinated (C) sensory afferent
fibers 3233). The neuropathic pain following nerve injury or tissue inflammation
depends on both an increase in the sensitivity of these first synapses at the site of injury
and an increase in the excitability of neurons in the CNs es•3436).
   Second-order neurons ascend the spinal cord to terminate in many supraspinal
structures throughout the brain stem, thalamus and cortex. In the thalamus, these
systems are divided into two main groups such as the ventrobasal complex and
intralaminar nuclei 36). The former, which includes the ventral posterolateral nuclei
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and ventral posteromedial nuclei, is involved in the sensory discriminative component
of pain and further projects to the somatosensory cortex 3638). The latter, which
includes the central medial nuclei and parafascicular nuclei, is associated with the
affective motivational aspects of pain and projects to the cingulate cortex (CG) 3638).
The manifestation of pain can be explained on the basis of neural substrates mediating
sensory, affective, and nociceptive functions, as well as neurovegetative responses.
While the sensory, discriminative-perceptive component permits spatial and temporal
localization, physical qualification and intensity quantification of the noxious stimulus,
the cognitive-affective component attributes emotional coloring to the experience, and
is responsible for the behavioral response to pain 39). Therefore, I believed it would be
worthwhile to investigate the ascending nociceptive transmission from the dorsal horn
to brain areas involved in the processing of noxious stimuli.
Use of opioids to treat chronic pain
   The y-opioid receptor serves as the principle physiological target for most clinically
important opioid analgesics. It has been shown that pt-opioid receptor transduces
signals through pertussis toxin (PTX)-sensitive Gi/Go proteins to inhibit adenylate
cyclase, increase membrane K' conductance, reduce Ca2' current co) and activate a
phospholipase C (PLC)-IP3 pathway depending on the stimulation of Py subunits `'`3).
   According to the World Health Organization (WHO) guidelines for patients with
moderate or severe pain, the typical pt-opioid receptor agonist morphine has been
considered a "gold standard" for the treatment of moderate to severe cancer pain. In
                                          '
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1965, fentanyl, an anilidopiperidine-class p-opioid agonist, was reported as a potent
synthetic analgesic. Fentanyl has a high affinity for pt-opioid receptors and its
analgesic activity is 50-100 times more potent than that of morphine. The low
molecular weight and lipid-solubility of fentanyl make it suitable for delivery via a
transdermal therapeutic system. On the other hand, oxycodone, which has been in
clinical use for many years, is a semi-synthetic opioid analgesic derived from the
naturally occurring alkaloid thebaine. It has been demonstrated that oxycodone has a
structure and lipid-solubility comparable to those of morphine, and is comparable or
only slightly inferior to morphine with regard to its analgesic potency "). In the
clinic, it has been reported that the peripheral administration of oxycodone is effective
for relieving some symptoms of pain in patients with neuropathtic pain. Thus,
opioids, such as morphine, fentanyl and oxycodone, have been recommended as the
drug of choice for the management of patients with chronic pain.
Opioid reward and mesolimbic dopamine system
   u-Opioid receptor agonists such as morphine and heroin have marked effects on
mood and motivation. They produce euphoria in humans and function as positive
reinforcers in various species, i.e., they maintain drug-seeking behaviors, which lead to
their administration. The reinforcing effects of these drugs may become so marked
that they become the primary stimuli that motivate behavior, with subsequent of
compulsive drug-seeking or addiction 45`7).
   Many studies have pointed to the mesolimbic dopaminergic system as the origin of
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this effect. The mesolimbic dopaminergic system originates in the ventral tegmental
area (VTA) of the midbrain and projects to nucleus accumbens (N.Acc.) that structures
closely associated with the limbic system. It has been implicated in the rewarding
effects of intracrainial self-stimulation, in natural rewards such as food and water intake,
and in the action of drugs of abuse, including opioids `8'`9). It is well documented that
p-opioid receptors located in the VTA are critical for opioid reward. An
electrophysiological study demonstrated that systemic administration of morphine
elicits an increase in the firing rate of dopaminergic neurons in the VTA so).
Furthermore, opioids have been shown to increase dopamine release and dopamine
metabolites in the mesolimbic dopamine terminal fields 5'-5$. Using the CPP paradigm,
intra-VTA administration of morphine produces a rewarding effect 56), and this effect is
blocked by either systemic naloxone 56) or intra-VTA injections of naloxone methiodide
5'). The morphine- or DAMGO-induced place preference is blocked by either
dopamine antagonists or neurochemical destruction of the N.Acc. 58'59). Additionally,
intra-VTA injections of the pt-opioid receptor antagonist
D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH, (CTOP) or naloxone induce place
aversion, and these effects are inhibited by 6-hydroxydopamine-induced lesions of the
N.Acc. `5). These findings indicate that dopamine-containing neurons of the midbrain
VTA, an area that possesses high densities of pt-opioid receptors, play a critical role in
the rewarding and aversive effects of opioids.
Morphine dependence under a chronic pain
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   Since relief from cancer pain was reported by the WHO to be achievable for most
people with cancer, morphine has been used mostly for severe pain. In Japan, the
annual consumption of morphine for medical purposes has increased. However, the
present amount of morphine consumed per capita in Japan is still less than one-sixth of
that in the United States oo). This means that many patients still continue to suffer
ongoing pain during the course of their illness. One major reason is that undue anxiety
about psychological dependence on morphine in cancer patients has caused physicians
and patients to use inadequate doses of opioids.
   It has often been proposed that opioid addiction does not arise when opioids are
used to treat pain. ' Some patients rarely show withdrawal signs when the pain is
relieved and the opioid drug is gradually withdrawn. In fact, this argument has been
used to support the safe use of opioids for the treatment of severe acute, cancer and
chronic pain 6"62). Indeed, animal and human studies support the contention that opioid
euphoria and reward are attenuated by pain 63'68). Interestingly, inflammatory
nociception leads to the activation of endogenous K-opioidergic systems in the brain
63•67•69). On the other hand, neuropathic pain due to sciatic nerve ligation causes the
dysfunction of pt-opioid receptor in the VTA 6S'66). These phenomena could be
responsible for the suppression of the morphine-induced rewarding effect associated
with the decrease in the release of dopamine in the brain of rodents. However, the
mechanism of the suppression of opioid reward under chronic pain remains unclear.
Anatomy and imaging
8
   Anatomical pathologists diagnose disease and gain other clinically significant
information through the examination of tissues and cells. This generally involves
gross and microscopic visual examination of tissues, with special stains and
immunohistochemistry to visualize specific proteins and other substances in and around
cells. More recently, anatomical pathologists have begun to use molecular biology
techniques to gain additional clinical information from these same specimens.
  Neuroimaging includes the use of various techniques to either directly or indirectly
  image the structure and function/pharmacology of the brain. Recent advances in
   functional neuroimaging techniques promise to promote our understanding of the
dynamics of the human brain in the perception of pain, i.e., central processing involving
    sensation, affection, association and cognition. A series of positron emission
   tomographic (PET), single photon emission tomographic (SPET), and functional
 magnetic resonance imaging (fMRI) studies on experimentally elicited phasic thermal
 and chemical pain, using regional cerebral blood flow (rCBF) as an index of neuronal
  activity, have consistently demonstrated the activation of the primary and secondary
   somatosensory area (SI, SII), anterior cingulate cortex (ACC), thalamus, insula,
  prefrontal cortex and cerebellum 70'B). These regions have thus been suggested to
  panicipate in the central processing of nociception. Therefore, it is considered that
 imaging techniques, such as immunohistochemistry and fMRI, may be used to reveal a
       relatively new discipline within medicine and neuroscience/psychology.
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                            Aim and Scope
   The aim of the present study was to investigate the mechanisms that underlie the
suppression of opioid reward under a neuropathic pain-like state in rodents. Behavioral,
neurochemical and biochemical experiments were conducted.
The specific aims of the proposed research are as follows:
In Chapter 1:
   To clarify the role of a spinal PKC/thrombin/protease--activated receptor (PAR)/
IPDGF-mediated signaling pathway in the development of the neuropathic pain-like
state induced by partial sciatic nerve ligation, I performed in vivo experiments using
hirudin, which is a specific and potent thrombin inhibitor, PDGF ct receptor
(PDGFRct)/Fc chimera protein and the PDGFR-dependent I'TK inhibitor.
Furthermore, in vitro studies were performed to investigate whether the
immunoreactivity to PAR-1 and binding of guanosine-5'-o-(3-[3SS]thio) triphosphate
([35S]GTPyS) to membranes of the spinal cord induced by thrombin could be affected by
sciatic nerve ligation.
In Chapter 2:
   To ascertain whether the direct activation of PKC in the spinal cord could change
brain activation, I investigated whether intrathecal injection of the PKC activator
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phorbol 12,13-dibutyrate (PDBu) could change the brain activation using the fMRI
method in mice with a deletion of the gene that encodes the neuron-specific PKCy
isoform.
In Chapter 3:
     To further examine whether activation of PKC in the spinal cord could lead to
changes in the brain endogenous opioidergic system in the brain, I investigated whether
a gene deletion for an endogenous p-opioid peptide P-endorphin could affect pain-like
behavior and the suppression of the morphine-induced rewarding effect by the direct
activation of PKC in the spinal cord.
In Chapter 4:
   To clarify the mechanism of the suppression of opioid reward under a chronic pain,
I investigated whether released P-endorphin could affect the suppression of the
opioid-induced rewarding effect, reduce p-opioid receptor function and decrease the
level of increased dopamine release in the nucleus accumbens under a neuropathic
pain--like state using P-endorphin knockout mice.
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Ethics
   The present study was conducted in accordance with the Guiding Principles for the
Care and Use of Laboratory Animals, as adopted by the Committee on Animal Research
of Hoshi University, which is accredited by the Ministry of Education, Culture, Sports,
Science and Technology of Japan. Every effort was made to minimize the numbers
and any suffering of animals used in the following experiments. Animals were used
only once in the present study.
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Chapter1
Protease-activated receptor-1 and platelet-derived
spinal cord neurons are implicated in neuropathic
injury
growth factor in
pain after nerve
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                             Introduction
   Recently, our understanding of the role of serine proteases such as thrombin, a key
enzyme of the coagulation system, has been expanded to include actions in the nervous
system '`). Thrombin affects protease-activated receptors (PARs), which are a family
of G protein-coupled receptors 7S. Molecular cloning has identified four PARs.
Thrombin activates PAR-1, PAR-3 and PAR-4. Thrombin cleaves PARs, unmasking
the "tethered ligand", an extracellular N-terminal domain that subsequently binds and
activates the receptor '6). It is considered that PARs are implicated in responses to
injury, notably in inflammation and repair 7D. In particular, PAR-1, which mediates
most of the known proinflammatory actions of thrombin, is expressed by platelets,
endothelial cells, fibroblasts, smooth muscle cells, mast cells, neurons and astrocytes 78).
Furthermore, PAR-1 is present in the developing and mature central nervous system '9).
Zhu et al. (2005) 80) reported that PAR-1 is expressed not only in a subset of large
diameter primary sensory neurons, but also in a subset of small and medium diameter
primary sensory neurons of the spinal cord which play an important role in the
transmission of pain. The thrombin inhibitor hirudin, which is isolated from leech
(Hirudo medicinalis), was characterized as a specific thrombin inhibitor in the late
1950s 8'). In addition, the high affinity of hirudin for thrombin and the specificity of
the tight and essentially irreversible binding of hirudin to thrombin has been recently
confirmed 82). Therefore, hirudin is a useful tool for the elucidation of mechanisms of
thrombin-induced physiological responses.
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    Recently, it has been reported that thrombin induces the activation of platelets and
promotes the expression or the release of PDGF from ct-granule of platelets zz). PDGF
was identified 20 years ago as a growth-promoting activity in human platelets for
fibroblasts, smooth muscle cells, and glial cells. There are three PDGF isoforms
(PDGF-AA, PDGF-AB, and PDGF-BB), which are homo- or heterodimers of related A
and B polypeptide chains. Two receptors for PDGF (PD6F ct receptor (PDGFRct) and
PDGFR6) bind the PDGF isoforms with different affinities. The PDGFRct binds all
three PDGF isoforms with similar affinities. The binding of PDGF to PDGFR has
been shown to induce homodimerization of the receptor, which facilitates the intrinsic
protein tyrosine kinase (PTK) activity of PDGFR 8`). The activation of PrK
autophosphorylates several tyrosine residues found within the cytoplasmic domain of
PDGFR and provides a recognition site for intracellular signal molecules.
Furthermore, it has been reported that PDGF and PDGFR could be located in
myelinated and unmyelinated primary sensory neurons 8S and in the spinal cord 86).
Thus, these findings support the idea that PDGF, which is mostly present in the blood
vessels, may play a more important role in the physiological responses including pain
perception than has been thought previously. In addition, as described above,
thrombin could release PDGF through PAR in platelets. Taken together, these
findings raise the possibility that PDGF associated with PAR may be implicated in pain
perception. However, the contribution of a thrombin/PARIPDGF pathway to the
neuropathic pain-like state is unknown.
    In the present study, therefore, I investigated the role of a spinal
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thrombin/PAR/PDGF-mediated signaling pathway in the development of the
neuropathic pain-like state induced by partial sciatic nerve ligation in mice.
16
Materials and Methods
Animals
    Male ICR mice (Tokyo Laboratory Animals Science Co., Ltd., Tokyo Japan)
weighing about 25 g were housed at a room temperature of 23Å}1Åé with a 12 hr
lightidark cycle (light on 8:OO am to 8:oo pm). Food and water available ad libitum
during the experimental period.
Neuropathic pain model
    The mice were anesthetized with sodium pentobarbita1 (70 mg/kg, i.p.). A panial
sciatic nerve injury by tying a tight ligature with 7-O or 8-O silk suture around
approximately 1/3 to 112 the diameter of the sciatic nerve on the right side (ipsilateral
side) under a light microscope (SD30, Olympus, Tokyo, Japan) as described previously
30). In sham-operated mice, the nerye was exposed without ligation.
Measurement of the latency of paw withdrawal in response to a thermal stimulus
    To assess the sensitiyity to thermal stimulation, each of the hind paws of mice was
tested individually using a thermal stimulus apparatus (model 33 Analgesia Meter; IITC
Inc./ Life Science Instruments, Woodland Hills, CA, USA). The intensity of the
thermal stimulus was adjusted to achieve an average baseline paw withdrawal latency of
approximately 8 to 10 sec in naive mice. Only quick hind paw movements (with or
without licking of hind paws) away from the stimulus were considered to be a
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withdrawal response. Paw movements associated with locomotion or weight shifting
were not counted as a response. The paws were measured alternating between the left
and right with an interval of more than 3 min between measurements. The latency of
paw withdrawal after the thermal stimulus was determined as the average of three
measurements per paw. Before the behavioral responses to the thermal stimulus were
tested, mice were habituated for at least 1 hr in an acrylic cylinder (15 cm high and 8 cm
in diameter). Under these conditions, the latency of paw withdrawal in response to the
thermal stimulus was tested. The latency of paw withdrawal in response to a thermal
stimulus was measured before surgery and 1, 3, 5, 7 and 14 days after surgery.
    To investigate the effect of a single i.t. treatment with thrombin or PDGF in normal
mice, the latency of paw withdrawal was measured before and after injection until the
latency returned to the baseline. The latency of paw withdrawal in response to a
thermal stimulus was determined as the average of both paws.
Measurement of paw withdrawal in response to a tactile stimulus
    To quantify the sensitivity to a tactile stimulus, paw withdrawal in response to a
tactile stimulus was measured using yon Frey filaments (North Coast Medical, Inc.,
Morgan Hill, CA, USA) with two different bending forces (O.02 g and O.16 g). Each
von Frey filament was applied to the plantar surface of the hind paws for 3 sec, and this
was repeated 3 times. Each of the hind paws of mice was tested individually. Paw
withdrawal in response to a tactile stimulus was evaluated by scoring as follows: O, no
response; 1, a slow and/or slight response to the stimulus; 2, a quick withdrawal
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response away from the stimulus without flinching or licking; 3, an intense withdrawal
response away from the stimulus with brisk flinching and/or licking. Paw withdrawal
in response to each filament was determined as the average of two scores per paw.
Paw movements associated with locomotion or weight shifting were not counted as a
response. The paws were measured alternating between left and right with an interval
of more than 3 min between the measurements. Before the behavioral responses to a
tactile stimulus were tested, mice were habituated for at least 1 hr on an elevated nylon
mesh floor. Under these conditions, paw withdrawal in response to a tactile stimulus
was tested. The paw withdrawal threshold to the tactile stimulus was measured before
surgery and the day after measurement of the thermal threshold (Day 2, 4, 6, 8 and 15).
To investigate the effect of a single i.t. treatment with thrombin or PDGF in normal
mice, the measurement of paw withdrawal responses to the tactile stimulus was
performed before and after the injection until the response returned to the baseline.
The paw withdrawal in response to the tactile stimulus was determined as the average of
both paws.
Intrathecal injection
    Intrathecal (i.t) injection was performed as described by Hylden and Wilcox
(1980) 87) using a 25-geL Hamilton syringe with a 30 1/2-gauge needle. The needle was
inserted into the intervertebral space between L5 and L6 of the spinal cord. A
reflexive flick of the tail was considered to be a sign of the accuracy of each injection.
The injection volume was 4 ptL for i.t. jnjection.
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   Groups of mice were repeatedly treated i.t. with the thrombin inhibitor hirudin (30
pmol/mouse), a recombinant mouse PDGFRct/Fc chimera protein (IO ng/mouse;
PDGFRct/Fc) or the PDGF receptor-dependent tyrosine kinase inhibitor AG17 (30
nmol/mouse) 30 min, 1 hr or 30 min, respectively, before surgery and once a day for 8
consecutive days after surgery. A single i.t. injection of thrombin (1 pmol/mouse) or a
recombinant human PDGF (O.1 pmol/mouse; PDGF) was performed in naive mice. I.t.
pretreatment with either hirudin or PDGFRctIFc was performed 30 min or 1 hr,
respectively, before a single i.t. injection of thrombin.
Guanosine-5'-o-(3-[35S]thio) triphosphate ([35S]GTPyS) binding assay
    Seven days after nerve ligation or sham operation, for membrane preparation,
spinal cords were rapidly excised at 40C. The tissue was homogenized using a
Potter-Elvejham tissue grinder with a Teflon pestle in 20 volumes (w/v) of ice-cold
Tris-HCI buffer containing 50 mM Tris-HCI (pH 7.4), 5 mM MgCI2 and 1 mM EGTA.
The homogenate was centrifuged at 4Åé for 10 min at 48,OOOXg. The pellet was
resuspended in [35S]GTPyS binding assay buffer containing 50 mM Tris-HCI (pH 7.4),
5 mM MgC12, 1 mM EGTA and 100 mM NaCl and centrifuged at 4Åé for 10 min at
48,ooOXg. The final pellet was resuspended in [35SjGTPyS binding assay buffer and
stored at -700C until use. The membrane homogenate (3-8 pg protein/assay) was
incubated at 250C for 2 hr in 1 ml of assay buffer with various concentrations of the
agonist, 30 ptM guanosine-5'-diphosphate (GDP) and 50 pM [35S]GTPyS (specific
activity, 10oo Ci/mmol; Amersham, Arlington Heights, IL, USA). The reaction was
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terminated by filtration using a Brandel cell harvester (Model M-24, Brandel, MD,
USA) and Whatman GF/B glass filters that had been presoaked in 50 mM Tris-HCI (pH
7.4), transferred to scintillation-counting yials containing O.5 mL of a tissue solubilizer
(Soluene-350, Packard Instrument Company, Meriden, CT, USA) and 4 mL of a
scintillation cocktail (Hionic Fluor, Packard Instrument Company), and equilibrated for
12 hr, and the radioactivity in the samples was determined with a liquid scintillation
analyzer. Non-specific binding was measured in the presence of 10 pM unlabeled
GTPyS. The binding of [35S]GTPyS was measured in the presence of GDP and the
absence of agonist. The data are expressed as the meanÅ}S.E.M. for percentage
stimulation. Similar results were obtained from at least three independent sets of
experiments. The membrane homogenate was incubated at 25Åé for 2 hr in 50 mM
Tris-HCI buffer (pH 7.4) with O.OOI-10 ptM thrombin (Wako Pure Chemical Industries,
Ltd., Osaka, Japan) in a total volume of 1 mL. The reaction was terminated using a
Brandel cell harvester (Model M-24, Brandel) and filtration through Whatman GFIB
glass filters that had been presoaked in 50 mh Tris-HCI (pH 7.4), O.Ol 9o (w/v)
polyethylenimine at 40C for 2 hr. Filters were washed three times with 5 mL of
Tris-HCI buffer (pH 7.4, 40C), and transferred to scintillation-counting vials containing
O.5 mL of tissue solubilizer (Soluene-350, Packard Instrument Company) and 4 mL of a
scintillation cocktail (Hionic Fluor, Packard Instrument Company). After 12 hr, the
radioactivity.in the samples was determined with a liquid scintillation analyzer (Model
1600CA, Packard Instrument Company). The values from Scatchard plot analyses
represent the meanÅ}S.E.M. of three independent experiments.
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Sample preparation
    Seven days after nerve ligation or sham operation, mice were deeply anesthetized
with sodium pentobarbital (70 mg/kg, i.p.) and intracardially perfusion--fixed with
freshly prepared 4 9o paraformaldehyde in O.IM phosphate-buffered saline (PBS, pH
7.4). After perfusion, the lumbar spinal cord was quickly removed and post-fixed in
4 9o paraformaldehyde for 2 hr, and permeated with 20 9o sucrose in O.IM PBS for 1
day and 30 9o sucrose in O.IM PBS for 2 days with agitation. The L5 lumbar spinal
cord segments were then frozen in an embedding compound (Sakura Finetechnical,
Tokyo, Japan) on isopentane using liquid nitrogen and stored at -30 Åé until use.
Frozen spinal cord segments were cut with a freezing cryostat (Leica CM 1510, Leica
Microsystems AG, Wetzlar, Germany) at a thickness of 10 pm and thaw-mounted on
poly-L-lysine-coated glass slides.
Immunohistochemistry
    The spinal cord sections were blocked in 10 9o normal goat serum (NGS) in
O.OIM PBS for 1 hr at room temperature. Each primary antibody [1:50-150 thrombin
R (PAR-1, Santa Cruz Biotechnology, Inc., CA, USA), 1:3000 protein kinase Cy (PKCy
Santa Cruz Biotechnology, Inc.), 1:120 PDGF-A (Santa Cruz Biotechnology, Inc.),
1:400 neuronal nuclei (NeuN, Chemicon International Inc., Temecula, CA, USA),
1:1000 SIOOP-subunit clone SH-Bl (SIOOS, Sigma-Aldrich Co., St. Louis, MO, USA)]
was diluted in O.Ol M PBS containing 10 9o NGS and incubated for 2 nights at 4 eC.
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The samples were then rinsed and incubated with an appropriate secondary antibody
conjugated with Alexa 488 and Alexa 546 for 2 hr at room temperature. Since the
staining intensity might vary between experiments, control sections were included in
each run of staining. The slides were then cover-slipped with PermaFluor Aqueous
mounting medium (Immunon'M; ThermoShandon, Pittsburgh, PA, USA). All sections
were observed with a light microscope (Olympus BX-80; Olympus) and photographed
with a digital camera (CoolSNAP HQ; Olympus).
RNA preparation and quantitative analysis by reverse transcription-polymerase
chain reaction (RT-PCR)
    Total RNA in the spinal cord of thrombin-injected or PBS-injected mice was
extracted using the SV Total RNA Isolation system (Promega, Madison, wr, USA)
following the manufacturer's instructions. Purified total RNA was quantified
spectro-photometrically at A2oo. To prepare first-strand cDNA, 1 ptg of RNA was
incubated in 100 ptL of buffer containing 10 mM dithiothreitol, 2.5 mM MgCl,, dNTP
mixture, 200 units of reverse transcriptase II (Life Technologies, Inc., USA) and O.1
mM oligo (dT)i2-is (Life Technologies, Inc.). The PDGF-A gene was amplified in a 50
ptL PCR solution containing O.8 mM MgCl,, dNTP mixture and DNA polymerase with
synthesized primers: a sense primer of PDGF-A, which is at position 407-423
(5'-CTGTGCCCATTCGCAGG-3') of the PDGF-A and an antisense primer at position
915-929 (5'-ACCGCACGCACATTG-3'), which was designed according to
GenBankTM sequence accession number AY324648. Samples were heated to 95 OC
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for 1 min, 55 OC for2min and 72 OC for3 min. The final incubation was 72 OC for7
min. The mixture was run on 2 9o agarose gel electrophoresis with the indicated
markers and primers for the internal standard glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The agarose gel was stained with ethidium bromide and
photographed with UV trans-illumination. The intensity of the bands was analyzed
and semiquantified by computer-assisted densitometry using NIH image software.
Values represent the meanÅ}S.E.M. of three independent experiments.
Drugs
    The drugs used in the present study were thrombin (Wako Pure Chemical
Industries, Ltd.), a thrombin inhibitor hirudin (Sigma--Aldrich Co.), PDGFRa/Fc (R&D
Systems, Inc., Minneapolis, MN, USA), a PDGF receptor-dependent tyrosine kinase
inhibitor AG17 ([(3,5-di-tert-butyl-4-hydroxybenzylidene)-malononitrile];
Calbiochem-Novabiochem Co., La Jolla, CA, USA) and PDGF (R&D Systems, Inc.).
Thrombin and PDGFRct/Fc were dissolved in sterile PBS (pH 7.4). Hirudin was
dissolved in O.9 9o sterile physiological saline. AG17 was dissolved in O.9 9o sterile
physiological saline containing 6 9o dimethyl sulfoxide (DMSO). PDGF was
dissolved in O. 1 9o bovine serum albumin (BSA) containing 4 mM HCI.
Statistical analysis
    All data are presented as the mean Å} S.E.M. The statistical significance of
differences between groups was assessed with two-way analysis of variance (ANOVA)
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or one-way ANOVA followed by the BonferronilDunn multiple comparison test or with
Student's t-test.
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Results
Thermal hyperalgesia and tactile allodynia induced by sciatic nerve ligation in
mice were significantly suppressed by repeated i.t. injection of the thrombin
inhibitor hirudin
   Partial ligation of the sciatic nerve caused a marked decrease in the latency of paw
withdrawal against a therma} stimulus only on the ipsilateral side in nerve-ligated mice
(vs. Saline-Sham group, F(1,7)=168.441, pÅqO.OOI, Fig. 1-IA). The thermal
hyperalgesia observed on the ipsilateral side in nerve-ligated mice was significantly
suppressed by repeated i.t. injection of hirudin (30 pmol/mouse) just before ligation and
once a day for 8 consecutive days after nerve ligation (vs. Saline-Ligation group,
F(1,9)=108.923, pÅqO.OOI, Fig. 1-IA).
   Mice with sciatic nerve ligation also showed a marked increase in paw withdrawal
in response to a tactile stimulus only on the ipsilateral side in nerve-ligated mice (vs.
Saline-Sham group, F(1,7)=69.829, pÅqO.OOI, Fig. 1-IB; vs. Saline-Sham group,
F(1,7)=l24.623, pÅqO.OOI, Fig. 1-IC). Under these conditions, repeated i.t. injection of
hirudin (30 pmol/mouse) significantly suppressed the increase in paw withdrawal in
response to an innocuous tactile stimulus induced by nerve ligation in mice (ys.
Saline-Ligation group, F(1,9)=40.565, pÅqO.OOI, Fig. 1-IB; vs. Saline-Ligation group,
F(1,9)=37.352, pÅqO.OOI, Fig. 1--IC). In addition, the recovery of the persistent
reduction in the thermal threshold by hirudin lasted even after treatment with hirudin
was terminated (from day 9 to day 15). (vs. Saline-Ligation group, F(1,9)=34.934,
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pÅqO.OOI, Fig. IB; vs. Saline-Ligation group, F(1,9)=51.586, pÅqO.OOI, Fig. 1-IC).
   Repeated i.t. injection of hirudin at the doses used in the present study failed to
affect thermal and tactile thresholds on the contralateral side in nerve-ligated mice and
on both sides in sham-operated mice (data not shown).
[35S]GTPyS binding by the PAR agonist thrombin to membranes of the spinal cord
was significantly increased in nerve-ligated mice
   The ability of the endogenous PAR ligand thrombin to activate G-proteins in the
spinal cord of sham-operated or nerve-ligated mice was examined by monitoring the
binding of [35S]GTPyS to spinal cord membranes. Thrombin (O.oo1-10 ptM) produced
a concentration-dependent increase in the binding of [35S]GTPyS to the L5 lumbar
spinal cord membranes obtained from sham-operated mice. In membranes of the
spinal cord from nerve-ligated mice, the increase in [3SS]GTPyS binding induced by
thrombin was significantly greater than that obtained from sham-operated mice
(F(1,90)=141.7, pÅqO.OOI, Fig. 1-2).
PAR-1-like IR in the dorsal horn of the mouse spinal cord was increased by sciatic
nerve ligation
    PAR-1-like immunoreactivity (IR) was detected on the ipsilateral side of the L5
lumbar spinal dorsal horn of sham-operated mice (Fig. 1-3A). Seven days after sciatic
nerve ligation, PAR-1-like IR in lamina II and III of the ipsilateral side of the L5 lumbar
spinal dorsal horn was increased compared to that observed in sham-operated mice (Fig.
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1-3B). Furthermore, the increased PAR-1-like IR in the spinal cord after nerve injury
was co-localized with PKCy, which is highly limited to neuronal cells in the inner part
of lamina II of the dorsal horn of the spinal cord (Fig. 1-4).
Thermal hyperalgesia and tactile allodynia induced by a single i.t. treatment with
thrombin in normal mice were suppressed by i.t pretreatment with hirudin
    I next inyestigated whether exogenous i.t. treatment with thrombin could cause a
hyperalgesic or allodynic response in normal mice. A single i.t. injection of thrombin
(1 pmol/mouse) produced marked thermal hyperalgesia and tactile allodynia in normal
mice after injection, and these effects lasted for 9-10 days after injection (vs.
Saline-PBS group, F(1,10)=605.881, pÅqO.OOI, Fig. 1-5A; vs. Saline-PBS group,
F(1,10)=138.103, pÅqO.oo1, Fig. 1-5B; vs. Saline--PBS group, F(1,10)=247.557, pÅqO.OOI,
Fig. 1-5C). The long-lasting thermal hyperalgesia and tactile allodynia caused by an
exogenous single i.t. injection of thrombin were abolished by i.t. pretreatment with the
thrombin inhibitor hirudin (30 pmol/mouse) (vs. Saline-Thrombin group,
F(1,10)=818.014, pÅqO.oo1, Fig. 1-5A; vs. Saline-Thrombin group, F(1,10)=81.366,
pÅqO.oo1, Fig. 5B; vs. Saline-Thrombin group, F(1,10)=111.593, pÅqO.OOI, Fig. 1-5C).
PDGF-A-like IR was detected in the neuron and astrocytes in the mouse spinal
cord
    I investigated the localization of PDGF-A in the L5 lumbar spinal cord in mice
using immunohistochemical analysis. PDGF-A-like IR was detected in the superficial
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laminae and inner part of the L5 lumbar spinal cord. Furthermore, PDGF-A-like IR
was principally co-localized with the neuron--specific nuclear protein marker
NeuN-positive cells in the superficial and inner part of the dorsal horn. Astrocytes in
the dorsal horn of the spinal cord were stained with SlooP, a specific marker for
astrocytes. PDGF-A-like IR was observed occasionally in SlooP-positive cells in the
dorsal horn of the spinal cord (Fig. 1-6).
Thermal hyperalgesia and tactile allodynia induced by sciatic nerve ligation in
mice were suppressed by repeated i.t. injection of PDGFRa/Fc
   Repeated i.t. injection of PDGFRctIFc (10 ng/mouse) just before and once a day for
8 consecutive days after nerve ligation reversed the decreased thermal and tactile
threshold on the ipsilateral side of nerve-ligated mice (vs. PBS-Ligation group,
F(1,10)=179.88, pÅqO.oo1, Fig. 1-7A; vs. PBS--Ligation group, F(1,10)=68.049, pÅqO.OOI,
Fig. 1--7B; vs. PBS-Ligation group, F(1,10)"7.454, pÅqO.OOI, Fig. 1-7C). The same
treatment had no effect on the latency of paw withdrawal after a thermal or tactile
stimulus on the contralateral side in nerve-Iigated mice and on both sides in
sham-operated mice (data not shown).
Thermal hyperalgesia and tactile allodynia induced by sciatic nerve ligation were
significantly reversed by repeated i.t. injection of the PDGF receptor-dependent
PTK inhibitor AG17
    To investigate whether the activation of protein tyrosine kinase (I'I'K) mediated by
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PDGF receptor could be directly involved in the neuropathic pain-like state induced by
nerve ligation, groups of mice were treated i.t. with the PDGF receptor-dependent I'I'K
inhibitor AG17 (30 nmollmouse) just before surgery and once a day for 8 consecutive
days after nerve ligation. The thermal hyperalgesia and tactile allodynia induced by
nerve ligation were significantly reversed by chronic i.t. treatment with AG17 (vs.
Vehicle-Ligation group, F(1,11)=116.508, pÅqO.oo1, Fig. I-8A ; vs. Vehicle-Ligation
group, F(1,11)=20.928, pÅqO.oo1, Fig. 1-8B ; vs. Vehicle-Ligation group,
F(1,11)=25.063, pÅqO.oo1, Fig. 1-8C). Such treatment had no effect on the latency of
paw withdrawal on the contralateral side in nerve-ligated mice or on both sides in
sham-operated mice (data fiot shown).
Thermal hyperalgesia and tactile allodynia induced by a single i.t. treatment with
PDGF in normal mice were suppressed by i.t. pretreatment with AG17
    To investigate whether PDGF could cause a hyperalgesic or allodynic response in
normal mice, groups of normal mice were treated i.t. with PDGF. A single i.t.
injection of PDGF (e.1 pmol/rnouse) produced marked thermal hyperalgesia and tactile
allodynia in normal mice after injection, and this effect lasted for 8-9 days after
injection (vs. Vehicle-PBS group, F(1,8)=164.250, pÅqO.OOI, Fig. 1-9A; vs.
Vehicle-PBS group, F(1,8)=197.951, pÅqO.OOI, Fig. 1--9B; vs. Vehicle-PBS group,
F(1,8)=93,523, pÅqO.OOI, Fig. 1-9C). The long-lasting thermal hyperalgesia and tactile
allodynia caused by an exogenous single i.t injection of PDGF were abolished by i.t.
pretreatment with the PDGF receptor-dependent PTK inhibitor AG17 (30 nmol/mouse)
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(vs. Vehicle-PDGF group, F(1,8)=376.449, pÅqO.OOI, Fig. 1-9A; vs. Vehicle-PDGF
group, F(1,8)=49.965, pÅqO.OOI, Fig. 1-9B; vs. Vehicle-PDGF group, F(1,8)=68.029,
pÅqO.OOI, Fig. 1-9C).
Thermal hyperalgesia and tactile allodynia induced by a single i.t. treatment with
thrombin in normal mice were significantly eliminated by repeated i.t.
pretreatment with PDGFRalFc
    Facilitation of the activation of a thrombin/PAR-1/PDGF pathway in the spinal
cord may play an important role in the development of the neuropathic pain-like state in
mice. The next study was undertaken to investigate whether spinal PDGF could be
involved in the thermal hyperalgesia or tactile allodynia observed with a single i.t.
injection of thrombin. The thermal hyperalgesia and tactile allodynia induced by a
single i.t. injection of thrombin were significantly eliminated by repeated i.t.
pretreatment with PDGFRct/Fc just before injection and once a day for 12 consecutive
days after injection (vs. PBS-Thrombin group, F(1,9)=463.624, pÅqO.OOI, Fig. 1-10A; vs.
PBS-Thrombin group, F(1,9)=38.222, pÅqO.OOI, Fig. 1-10B; vs. PBS-Thrombin group,
F(i,9)=70.964, pÅqO.OOI, Fig. 1-10C). Under these conditions, there were no
differences between PBS- and thrombin-injected mice with regard to mRNA levels of
PDGF-A in the spinal cord (Fig. 1-11).
PAR-1-positive cells were clearly co-localized with PDGF-A-like immunoreactivity
in the dorsal horn of the spinal cord of nerve-ligated mice
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    The key approach in the present study was to investigate the co-localization of
PAR-1 with PDGF-A in the dorsal horn of the spinal cord of nerve-ligated mouse.
Interestingly, almost all of the PAR-1--positive cells in the dorsal horn of the spinal cord
of nerve--ligated mice were clearly co-localized with PDGF-A--like IR, indicating that
PDGF-A-like IR is highly located on PAR-1--positive neuronal cells (Fig. 1-l2).
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Fig. 1-1 Effect of repeated intrathecal (i.t.) injection of a thrombin inhibitor, hirudin, on
thermal hyperalgesia (A) and tactile allodynia (B and C) in sham-operated or nerve-ligated
mice. Tactile stimulus was applied using filaments with two different bending forces [O.02
g (B) and O.16 g (C)]. Groups of mice were repeatedly treated i.t. with hirudin (30 pmol
/mouse) or saline 30 min prior to surgery (day O) and once a day for 8 consecutive days after
surgery. From day 9 to day 15 after surgery, mice were not treated with hirudin. Each
point represents the mean Å} S.E.M. of 5-7 mice. **pÅqO.Ol and ***pÅqO.OOI vs.
Saline-Sham group, ##pÅqO.Ol and ###pÅqO.OOI vs. Saline-Ligation group.
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Fig. 1-2 Comparison of the stimulation of l35SIGTPyS binding by the PAR agonist
thrombin to membranes of the spinal cord obtained from sham-operated or nerve-ligated
mice. Sample preparation was performed at 7 days after nerve ligation. The spinal cord
membranes were incubated with {35S]GTI'yS (50 pM) and GDP (30 pM) with or without
thrombin. The data are shown as the percentage of basal f35S]GTPyS binding measured in
the presence of GDP and the absence of thrombin. Values represent the mean Å} S.E.M. of
3 samples. F(1, 90)=l41.7, pÅqO.OOI vs. Sham group.
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Fig. 1-3 Increase in PAR-1-like immunoreactivity (IR) on the ipsilateral superficial dorsa]
horn of the L5 lumbar spinal cord in nerve-ligated mice (B-i and B-ii) compared to that in
sham-operated mice (A-i and A-ii). Spinal cord slices were prepared 7 days after sham
operation or nerve ligation in mice. Scale bars; 50 pm (A-i and B-i), 10 pm (A-ii and B-ii).
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Fig. 1-4 Co-localization of PAR-1 (A) with PKCy, which is highly limited to the inner part
of lamina II in the dorsal horn of the mouse spinal cord (B). The .ereen labeling for PAR-j
and the red labeling for PKCy show co-localization in the dorsal horn of the spinal cord (C-i,
-
ii). PAR-1-like IR is seen in the membrane of PKCy-label)ed cells in the dorsal horn of
the spinal cord (arroNv head in C-ii). Scale bars=50 pm (A, B and C-i), 10 1.tm (C-ii).
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Fig. 1-5 Effect of a single i.t. injection of thrombin on paw withdrawal responses to the
thermal (A) and tactile (B and C) stimulus in normal mine. Tactile stimulus was performed
using filament with two different bending forces [O.02 g (B) and O.16 g (C)]. Group of
mice were repeatedly treated i.t. with a thrombin inhibitor hirudin (30 pmoYmouse) or saline
30 min before a single i.t. injection of thrombin and once a day for 12 consecutive days after
injection. Each point represents the mean Å} S.E.M. of 6 mice. "'pÅqO.OOI vs.
Saline-PBS group, ##pÅqO.Ol and ###pÅqO.OOI vs. Saline-Thrombin group.
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Fig. 1-6 Co-localization of Pl)GF--A(A, D) Nvith NeuN. a neuron-specific nuc]ear
protcin marker. ÅqB) or S1OOII. a specit-ic marker for astrocÅr'tes, ( Fl) in the dorsa] horn of the
mous.e spinal cord. The g,reen Iabelin.g for PD. GF-A and the red labeling for NeuN or
SIOO13 sho" co-localization in the dorsal horn of the g.pinal cord (("-i. -ii or F-i. -ii).
PI)GF-A-like IR is e/ clusivelÅr' obg.erved on NeuN-labelled ccllt (('-ii) and partiallÅr
observcd' on SIOOII-]abelled cells in the dorsal horn of the spinal cord (F-ii). Scale bars=50
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Fig. 1-7 Effect of repeated i.t injection of PDGFRct/Fc on thermal hyperalgesia (A) and
tactile allodynia (B and C) in sham-operated or nerve-ligated mice. Tactile stimulus was
applied using fiilaments with two different bending forces [O.02 g (B) and O.16 g (C)1.
Groups of mice were repeatedly treated i.t. with PDGFRotlFc (1O ng/mouse) or sterile PBS 1
hr prior to surgery (day O) and once a day for 8 consecutive days after surgery. Each point
represents the mean Å} S.E.M. of 5-6 mice. ***pÅqO.OOI vs. PBS-Sham group, ##pÅqO.Ol
and ###pÅqO.OOI vs. PBS-Ligation group.
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Fig. 1-8 Effect of repeated i.t. injection of an inhibitor of PDGF receptor-mediated M"K,
AG17, on thermal hyperalgesia (A) and tactile allodynia (B and C) in sham-operated or
nerve-ligated mice. Tactile stimulus was applied using filaments vvith two different
bending forces [O.02 g (B) and O.16 g (C)]. Groups of mice were repeatedly treated i.t.
with AG17 (30 nmol/mouse) or vehicle 30 min prior to surgery (day O) and once a day for 8
consecutive days after surgery. Each point represents the mean Å} S.E.M. of 5-7 mice.
"" pÅqO.Ol and ***pÅqO.OOI vs. Vehicle-Sham group, ##pÅqO.Ol and ###pÅqO.OOI vs.
Vehicle-Ligation group.
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Fig. 1-9 Effect of a single i.t. injection of PDGF on paw withdrawal responses to the
thermal (A) and tactile (B and C) stimulus in normal mine. Tactile stimulus was performed
using filament with two different bending forces [O.02 g (B) and O.16 g (C)]. Group of
mice were repeatedly treated i.t. with an inhibitor of PDGF receptor-mediated PTK, AG17
(30 nmollmouse) or vehicle 30 min before a single i.t. injection of PDGF and once a day for
11 consecutive days after injection. Each point represents the mean Å} S.EM. of 6 mice.
"pÅqO.05, *"pÅqO.Ol and *""pÅqO.OOI vs. Vehicle-PBS group, #pÅqO.05, ##pÅqO.Ol and
###pdl.OOI vs. Vehicle-PDGFgroup.
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Fig. 1-10 Effect of repeated i.t. injection of PDGFRct/Fc on thermal hyperalgesia or tactile
allodynia induced by a single i.t. injection of thrombin in normal mice. Groups of mice
were repeatedly treated i.t with PDGFRoe/Fc (10 nglmouse) or sterile PBS 1 hr prior to the
single i.t. injection of thrombin (1 pmollmouse) and once a day for 12 consecutive days after
injection. Each point indicates the mean Å} S.E.M. of 6 mice. **pÅqO.Ol and ***pÅqO.OOI
vs. PBS-PBS group, #pÅqO.05, ##pÅqO.Ol and ###pÅqO.OOI vs. PBS-Thrombin group.
42
t.x,
-lli• hv
L,;intr ] ;
vl•/s rl//,
  t, hr
'H 4 .i
,/.t,,, 1,[J,S IIII.ILI,-,11
1 ,g4")
f, T, S ,)
t 'Fi" 1 ,/,,-d'[:/ }'1{N T '.,m'I.,'t/
  -kr Idnx
]ill"E ,X G,Wl]H
tl{i
 t:tli'
 ECel)
  so-
J t")
  •aU-
  )"
  o
i,EJS ' klw"mbiii ljlsS 'ihli.;ITslMll
e' 1 SLT hi.],
Fig. 1-11 Representative RT-PCR for PDGF-A (lanes 2-5) and an internal standard
GAPDH (lanes 6-9) (A) mRNAs in the spinal cord at 6 hr and 1 day after a single i.t.
injection of PBS (lanes 2, 4, 6, 8) or thrombin (l pmollmouse) (lanes 3, 5, 7, 9) in mice.
Lane 1 is the indicated marker. The intensity of the bands was determined in a
semi-quantitative manner using NIH Image (B). Each yalue for PDGF-A mRNA in
thrombin-injected mice was normalized by the yalue for the respective GAPDH mRNA.
The values in thrombin-injected mice are expressed as a percentage of the increase in
PBS-injected mice. Each column represents the mean Å} S.EM. of 10 samples.
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Fig. 1-12 Co-localization of PAR-1 (A) "ith PDGF-A(B) in the dorsal horn of the mouse
spinal cord, rl-he green labeling for PAR-l and the red labeling for PDCJF-A shoNv apparent
co-localization in the dorsal horn of the spinal cord (C-i, -ii). PDGF-A-like IR is almost all
seen in the cytoplasm of PAR-1-labeled cells in the dorsal horn of the spinal cord (arrow
head in C-ii). Scalc bars=50 um (A, B and C-i), iO FLm (C.-ii).
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                               Discussion
   A very large number of studies have confirmed that a serine protease, thrombin, is a
major stimulus for platelets, and initiates a series of co-ordinated events that result in
platelet aggregation in vitro or in vivo '5). In addition to its well-known role in the
platelet aggregation cascade, thrombin has been implicated in degenerative as well as
protective mechanisms in the CNS. It is of interest to note that PAR-1, one of the
thrombin receptor subtypes, is expressed in a subset of small and medium diameter of
primary sensory neurons, suggesting that a thrombin/PAR-1 pathway play a possible
role in the transmission of pain 80). It has been reported that responses to thrombin
were found to be blocked by the specific thrombin inhibitor hirudin, a hirudin-derived
peptide, which reflects the thrombin-specific nature of the cloned receptor. Several
studies have demonstrated that the response to thrombin is unrelated to the proteolytic
properties of the enzyme, but rather the hirudin-like binding domain appears to be the
important feature of the protein. Mutation of the N-terminus identified the presence of
a hirudin--like domain that was essential for high-affinity binding and the potent effects
of thrombin '5). The hirudin-like thrombin binding sequence has been identified in
PAR-1. This would perhaps allow high-affinity binding to PAR-1 in the hirudin-like
binding domain. In the present study, I first investigated the role of a spinal
thrombin/PAR-1 pathway in the development of a neuropathic pain-like state in mice.
Thermal hyperalgesia and tactile allodynia induced by sciatic nerve ligation were
 significantly suppressed by i.t. pretreatment with hirudin just before and once a day for
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the first 7 days after surgery. Interestingly, the recovery of the persistent reduction in
the thermal threshold by hirudin lasted even after treatment with hirudin was
discontinued, which indicates the importance of the initial blockade of PAR-1 for
inhibiting the development of a neuropathic pain--like state. In the preliminary study, I
also investigated whether the thrombin/PAR-1 pathway within the spinal cord could be
involved in the maintenance, as well as the development, of a neuropathic pain-like
state in mice. The developed neuropathic pain-like state was significantly suppressed
even by repeated i.t. post-treatment with hirudin, which was started from 7 days after
sciatic nerve ligation (thermal hyperalgesia; 66.4Å}2.68 9o of maximum inhibition,
tactile allodynia; 82.5Å}7.85 9o of maximum inhibition). These results suggest that the
thrombin/PAR-1 pathway within the spinal cord may also contribute to the maintenance
of a neuropathic pain-like state. Furthermore, I demonstrated here that an exogenous
single i.t. injection of thrombin produced long-lasting thermal hyperalgesia and tactile
allodynia in normal mice. These responses were abolished by i.t. pretreatment with
hirudin. These findings indicate that the spinal thrombinlPAR--1 pathway may be
directly involved in the development of a neuropathjc pain-like state caused by nerve
ligation in mice.
   Additional evidence for the contribution of a spinal thrombinlPAR-1 pathway to a
neuropathic pain-like state was obtained by an [35S]GTPyS binding assay and
immunohistochemical approach. Possible changes in PAR-1 function in the spinal
cord of nerve--ligated mice were evaluated by monitoring the binding of [35S]GTPyS to
membranes of the mouse spinal cord. In membranes of the L5 lumbar spinal cord
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from nerve-ligated mice, the concentration-dependence curve for the increased
[35S]GTPyS binding induced by thrombin was significantly greater than that obtained in
sham-operated mice. Furthermore, an immunohistochemical study showed that sciatic
nerve ligation produced a clear increase in PAR-1-like IR on lamina II and III of the
ipsilateral side of the L5 lumbar spinal dorsal horn compared to that observed in
sham-operated mice. The subpopulations of PAR-1-like IR in the spinal cord were
co-labelled with PKCy-like IR, which is highly limited to neuronal cells in the inner part
of lamina II of the dorsal horn of the spinal cord, indicating that PAR-1 in the dorsal
horn of the L5 lumbar spinal cord may be mostly located in neurons. These findings
provide further evidence that a thrombin/PAR-1 pathway within neuronal cells of the L5
lumbar spinal cord plays a critical role in the developrpent of a neuropathic pain-like
state.
   PDGF was first identified in a search for serum factors that stimulate the
proliferation of arterial smooth muscle cells zzÅr. Although the ct-granule of platelets is
a major storage site for PDGF, recent studies have shown that PDGF can be synthesized
by several different cell types 86). In the present study, PDGF-A-like IR was detected
in the superficial laminae and inner part of the L5 lumbar spinal cord in mice.
Furthermore, PDGF-A-like IR in the spinal cord was predominantly located on neuronal
cells and occasionally located on astrocytes. Under these conditions, I found here for
the first time that thermal hyperalgesia and tactile allodynia induced by sciatic nerve
ligation were significantly suppressed by repeated i.t. treatment with PDGFRctIFc,
which can trap respective endogenous PDGE resulting in the prevention of receptor
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activation. Furthermore, a single i.t. injection of PDGF produced marked thermal
hyperalgesia and tactile allodynia in normal mice after injection, and these effects lasted
for 8-9 days after injection. These responses were abolished by i.t. pretreatment with a
potent inhibitor of PTK activity linked to PDGF receptors, AG17. The reduction in
the latency of paw withdrawal on the ipsilateral side in nerve-ligated mice was
abolished by repeated i.t. injection of AG17. Considering these findings, the present
data suggest that the release of PDGF within the spinal cord by nerve ligation may lead
to the development of a neuropathic pain-like state in mice.
    Recently, thrombin has been shown to activate platelets and promote the
expression or the release of PDGF,from platelets. It has also been suggested that the
activation of thrombin receptor leads to several intracellular signaling events as well as
to the stimulation of endogenous PDGF-A production 83). In the present study, I
demonstrated here that PDGF-A-like IR was detected in the neuronal cells and
astrocytes within the L5 lumbar spinal cord. It is of interest to note that PDGF-A-like
IR was co-localized with PAR-1 in the dorsal horn of the L5 lumbar spinal cord.
Taken together, these findjngs raise the fascinating possibility that the activation of
PAR-1 by thrombin may facilitate the expression or the release of PDGF in neurona}
cells and astrocytes located in the spinal cord.
      The next study was then undertaken to investigate whether spinal PDGF could
be involved in thermal hyperalgesia or tactile allodynia mediated through the
thrombinlPAR-1 pathway. The thermal hyperalgesia and tactile allodynia induced by
a single i.t. injection of thrombin were significantly eliminated by repeated i.t.
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pretreatment with PDGFRct/Fc just before injection and once a day for 9 consecutive
days after injection. Under these conditions, there were no differences between PBS-
and thrombin-injected mice with regard to mRNA levels of PDGF-A in the spinal cord.
These results suggest that thrombin may activate PDGF-A-containing fibers in the
spinal cord without changing the expression of PDGF-A mRNAs, resulting in the
induction of hyperalgesia.
    In a subsequent study, I investigated the co-localization of PAR-1-containing cells
with PDGF-A in the dorsal horn of the spinal cord of nerve-ligated mice. Interestingly,
almost all of the PAR-1-like IR-positive cells in the dorsal horn of the spinal cord of
nerve-ligated mice were clearly co-labelled with PDGF-A-like IR, indicating that
PDGF-A is mostly located on PAR-1-containing neuronal cells.
  Released PDGF acts on PDGF receptor. It is well recognized that the activation of
PDGF receptor and its autophosphorylation serve as docking sites for adapter proteins
and enzymes such as phosphoinositide-3 kinase (PI-3 kinase), phospholipase C (PLC)y
and the Src family of tyrosine kinases 86). Especially, the activation of PLCy triggers
the facilitation of PKC, which inyolves in the development of a neuropathic pain-like
state 89'co), through the production of diacylglycerol and inositol 1,4,5-triphosphate (IP3).
Furthermore, BDNF, which was observed almost entirely on pre-synaptic neurons of the
L5 lumbar mouse spinal cord, is an important modulator of the expression of
neurotrophin associated with the activation of PKC 9i'92). However, I found here that
PDGF-A-positive cells are predominantly located on post-synaptic neurons and are
widely expressed in the outer and inner parts of the laminae of the spinal cord in mice.
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These findings suggest that spinal PDGF may be more essential for the development of
the neuropathic pain-like state induced by nerve ligation in mice. Although I clearly
show here that both PAR-1 and PDGF are responsible for this type of the neuropathic
pain-like state, I can not completely exclude the possibility that these two components
are just necessary for the present model to be developed. Thus, farther investigation is
needed to identify the role of PAR-1 and PDGF in other types of chronic pain models.
    In conclusion, the present data provide novel evidence that PAR-1/PKCy
/PDGF-A-mediated signaling pathway within the spinal cord are directly involved in the
development of the neuropathic pain-like state induced by sciatic nerve ligation in mice.
Such findings raise the fascinating possibility that the activation of up-regulated PAR-1
located on the spinal dorsal horn neurons following nerve injury may cause a
PKCy-dependent PDGF release in the spinal cord and in turn activate PDGFRct, leading
to a neuropathic pain-like state.
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Chapter 2
Implication of spinal protein kinase Cy isoform in activation of the
mouse brain by intrathecal injection of the protein kinase C activator
phorbol 12,13-dibutyrate using functional magnetic resonance imaging
analysis
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Introduction
   The PKC family of enzymes plays an important role in signal transduction in several
physiological processes 93). The PKC family consists of at least 12 isoforms that differ
with regard to their structure, substrate requirements, expression and localization, and
therefore may underlie diverse physiological functions 9`'95). A growing body of
evidence suggests that the activation of PKC in the spinal cord is implicated in changes
in pain perception so'96). Interestingly, mice that lack the PKCy isozyme show normal
responses to acute pain stimuli but show reduced signs of neuropathic pain after partial
ligation of the sciatic nerve, which suggests that the PKCy isozyme is involved in the
processing of nociception in the spinal cord 30). This contention can be supported by
the finding described in Chapter 1 that PKCy is a key player to modulate a neuropathic
pain-like state following sciatic nerve ligation in mice. It has been also reported that a
single i.t. injection of a specific PKC activator, phorbol 12,13-dibutyrate (PDBu),
produced long-lasting thermal hyperalgesia and pain-like behavior as indicated by
severe tail--shaking, vocalization, scratching and biting behaviors in mice 2"28).
   Functional magnetic resonance imaging (fMRI) can be used to investigate spatial
and temporal brain activation evoked by physiological and pharmacological
interventions. The benefits of this approach over conventional ex vivo methods
include its non-invasive nature and the ability to monitor rapid temporal changes in
brain activity at high anatomical resolution 9'). flVIRI has been used to evaluate central
nervous system processing of experimental pain in humans 39'98). Noxious heat
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stimulation in humans activates several brain regions, including the thalamus, basal
ganglia, insula, cingulate cortex, somatosensory, premotor and motor cortices,
prefrontal and inferior parietal cortex eqJi02). Animal studies on spinal cord and brain
activation following noxious stimulation have used autoradiography with
2-deoxyglucose and the radiotracer P9MTc] exametazime, and more recently fMRI.
Recent fMRI studies in rat models of pain have focused on activation of the cortical
area and thalamus, as determined by the blood oxygen level-dependent (BOLD)
contrast method, following noxious stimulation with the intraplantar injection of
formalin or capsaicin ios"on). However, the effects of neuropathic pain-like
transmission evoked by the activation of spinal PKC on the BOLD response,
panicularly with regard to the relationship between the spatial profile and the
time-course of activation, are unknown.
   The purpose of this study was to investigate whether direct spinal PKC activation
could cause a change in brain activation using the fMRI method in mice with a deletion
of the gene that encodes the neuron--specific PKCy isoform.
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Materials and Methods
   Animals
   PKCy knockout mice and their wild-type mice were used in the present study. PKCy
knockout mice were maintained on mixed genetic background of C57BL/6J and 129Sv
(The Jackson Laboratory, Bar Harbor, ME). Animals were housed in a room
maintained at 23 Å} 1 OC with a 12 hr lightidark cycle (light on 8:oo A.M. to 8:oo
P.M.). Food and water were available ad libitum.
Intrathecal (i.t.) injection
   Intrathecal (i.t.) injection was p
1.
erformed following the method described in Chapter
Functional imaging
   Mice were anaesthetized using isoflurane immediately after i.t. injection of PDBu or
vehicle. Animals were then transferred to a cradle designed to fit inside the probe of
the MR system and supplied with 19e isoflurane via a fitted mask. A continuous fMRI
scanning protocol was used to study changes in brain signal intensity using T2-weighted
BOLD contrast, and the intrathecal injection of PDBu (Sigma-Aldrich Co., MO, USA).
BOLD responses were measured hourly from 1 hr to 6 hr at all brain levels.
   Experiments were performed with a Unity Inova spectrometer (Varian, Palo Alto,
CA) which was interfaced to a 9.4T/31-cm horizontal bore magnet equipped with
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actively shielded gradients capable of 300 mT/m in a risetime of 500 sec (Magnex
Scientific, Abingdon, UK). High-resolution anatomical scans were collected using a
fast spin echo pulse sequence (TR = 2ooO ms, TE = 45 ms, FOV = 25.6 x 25.6 mm2, 1.0
mm slice thickness, 256 x 256 data matrix)
   Functional images were obtained with a multi--slice gradient-echo fast imaging
sequence (TE = 25 msec, TR = 70 msec, 300 flip angle, 128 x 128). One-mm-thick
slices were acquired simultaneously over a field of view (FOV) of 25.6 mm2 with an
acquisition time of approximately 32 sec. Typically, 3-6 images were collected at
baseline, followed by PDBu injection.
   Regions of interest (ROIs) were selected and statistical analyses were performed
using the image-analysis software ImageJ (Wayne Rasband, http://rsb.info.nih.gov/ij/;
Karl Schmidt http://www.quickvol.com). ROIs were drawn according to an atlas of
the mouse brain '05). BOLD signal intensity values in each ROIs were extracted and
normalized to the time of baseline (expressed as a percent change from baseline).
Statistical analysis was performed to compare percent changes in BOLD signal intensity
and activated pixels between baseline and each time point after PDBu injection. Pixels
whose BOLD percentage change relative to the baseline period was significantly
different at a 959o confidence level were overlaid onto the reference anatomical data set.
Drug
55
   The drug used in the present study was a specific PKC activator PDBu (Sigma Co.,
St Louis, Mo., USA). PDBu was dissolved in 109o dimethyl sulfoxide (DMSO)
containing O.99o saline.
Statistical data analysis
   The data are presented as the mean Å} SEM. The statistical significance of
differences between groups was assessed by one- or two-way analysis of variance
(ANOVA) followed by the BonferronilDunnett test or by Student's t-test.
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                                 Result
  I investigated the changes in BOLD signal intensity in several brain regions
following the direct activation of spinal PKC in mice. As shown in Fig.13, i.t.
injection of PDBu caused a robust positive signal activity in several brain regions of
wild-type mice compared with the basal intensity. Although the signal intensity in
these regions was significantly increased, notable differences among these regions were
seen in the time-course and levels of activation. The somatosensory cortex, lateral
thalamic nuclei and medial thalamic nuclei, which are sensory-discriminative
components of pain, were clearly activated following i.t. injection of PDBu in wild-type
mice (Fig.2A - 2C). In the somatosensory cortex, i.t. injection of PDBu produced a
dramatic and time-dependent increase in signal intensity at 1-6 hr after the injection (Fig.
2A-iii, *pÅqO.05, **pÅqO.Ol, **'pÅqO.OOI vs. basal intensity; vehicle in wild-type vs.
PDBu in wild-type, Fi,ias=8.449, PÅqO.OOOI). The thalamic areas were activated with
relatively moderate increases in signal intensity by the i.t. injection of PDBu at 1-6 hr in
wild-type mice (medial thalamus: Fig. 2B-iii, *pÅqO.05, **pÅqO.Ol vs. basal intensity;
vehicle in wild-type vs. PDBu in wild-type, Fi,irs=3.094, PÅqO.Ooo1. Iateral thalamus:
Fig. 2C-iii, **pÅqO.Ol vs. basal intensity; vehicle in wild-type vs. PDBu in wild-type,
Fi,irs=5.104, PÅqO.OOOI). These effects were abolished in mice which lacked the PKCy
gene (Fig. 2A-iii - 2C-iii).
   The cingulate cortex, nucleus accumbens and ventral tegmental area, which are
affective-motivational components of pain, including the mesolimbic dopaminergic
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system, were also activated following i.t. injection of PDBu in wild-type mice (Fig. 2D
-
 2F). In the cingulate cortex, i.t. injection of PDBu produced a robust and significant
increase in signal intensity at 3-6 hr (Fig. 2D-iii, *pÅqO.05, **pÅqO.Ol vs. basal intensity;
vehicle in wild-type vs. PDBu in wild-type, F,.,,=2.341, PÅqO.OOOI), but not at 1-2 hr.
Activation of the mesolimbic areas that contain the nucleus accumbens and ventral
tegmental area was noted with a only slight, but still significant, increase in signal
jntensjty by i.t. injectjon of PDBu in wild-type mice (Fig. 2E - 2F). An i.t injection of
PDBu increased the signal intensity at 4-6 hr in the nucleus accumbens (Fig. 2E-iii,
** pÅqO.Ol vs. basal intensity; vehicle in wild-type vs. PDBu in wild-type, Fi,m=2.425,
PÅqO.OOOI) and at 3-6 hr in the ventral tegmental area (Fig. 2F-iii, *pÅqO.05, **pÅqO.Ol vs.
basal intensity; vehicle in wild-type vs. PDBu in wild-type, I7,,gs=1.380, PÅqO.OOOI).
These effects were eliminated iR mice which lacked the PKCy gene (Fig. 2D-iii - 2F-iii).
Under these conditions, control mice that had been injected i.t. with vehicle (I09o
DMSO in saline) did not show activation in any regions in mice of both genotypes (Fig.
2A-iii - 2F-iii).
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Fig. 2
   Time-course of the effect of i.t. injection of PDBu on BOLD signal intensity in several brain regions in
wild-type and PKCy knockout mice. Intrathecal injection of PDBu produced a significant increase in BOLD
signal compared with vehicle in wild-type mice, Representative high-resolution anatomical image shows
regions of interest of the somatosensory cortex (A-i), lateral thalamus (B-i), medial thalamus (C-i), cingulate
cortex (D-i), nucleus accumbens (E-i) and ventral tegmental area (F-i) in a coronal section. Representative
activation maps (overlaid on anatomy) correspond to composite images of O hr or 6 hr after i,t, injection of PDBu
in wild-type mice and PKCy knockout mice (A-ii : somatosensory cortex, B-ii : lateral thalamus, C-ii : medial
thalamus, D-ii : cingulate cortex, E-ii : nucleus accumbens, F-ii : ventral tegmental area), Intrathecal injection
of PDBu produced a significant increase in BOLD signal compared with vehicle in wild-type mice (A-iii :
somatosensory cortex, B-iii : the lateral thalamus, C-iii : medial thalamus, D-iii : cingulate cortex, E-iii : nucleus
accumbens, F-iii:ventral tegmental area), Each point indicates the mean Å} S.E,M. of 6-15 images, 'pÅqO,05,
** pÅqO.Ol, ***pÅqO.OO1, each post i.t, PDBu treatment intensity vs. basal intensity.
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                               Discussion
   It has been reported that PDBu as a phorbol ester binds to all PKC isotypes
excluding aPKCs i06). It is well recognized that the up-regulation of PKC activity in
the spinal cord is a key factor for the induction of thermal hyperalgesia following nerve
ligation. It has been reported that a single i.t. injection of PDBu produced a persistent
pain-like state 2"28). Furthermore, I confirmed an increase in the phosphorylation of all
three subgroups (classic-type, novel-type and atypical-type) of PKC in the dorsal horn
of spinal cord in mice following sciatic nerve ligation (data not shown). It is
considered to be worthwhile to investigate ascending nociceptive transmission from the
dorsal horn of spinal cord areas to brain areas involved in the processing of noxious
stimuli induced by the activation of spinal PKCs. In the present study, I found that i.t.
injection of PDBu caused a robust positive signal activity in several brain regions of
wild-type mice compared with basal intensity. In contrast, these effects were
eliminated in PKCy gene knockout mice. These results suggest that the activation of
several brain regions caused by spinal PKC activation is substantially dependent on
spinal PKCy isoform activation.
   Another key finding of the present study was that there were notable differences in
brain activation by the i.t. injection of PDBu among brain regions with regard to the
time-course and level of activation. In the somatosensory cortex and lateral and
medial thalamic nuclei of wild-type mice, i.t. injection of PDBu produced a significant
increase in signal activity at 1-6 hr after the injection compared with basal intensity.
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These effects were abolished in PKCy gene knockout mice. In contrast, i.t. injection of
PDBu induced a significant increase in signal intensity at 3-6 hr in the cingulate cortex,
at 46 hr in the nucleus accumbens and at 3-6 hr in the ventral tegmental area. These
results suggest that delayed activation can be clearly noted in the affective-motivational
components of pain in i.t. PDBu-injected wild-type mice.
   In conclusion, my analysis of PKCy knockout mice supports the notion that loss of
the PKCy gene prevents the transmissioR of nociceptive information from the dorsal
horn of the spinal cord to brain areas involved in the processing of noxious stimuli
following i.t injection of PDBu. I propose here that the activation of spinal PKCy
associated with the activation of ascending pain transmission may be an important
factor in the development of a neuropathic pain-like state Iinked to emotional
dysfunction.
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Chapter3
Implicatien of endogenous P-endorphin in the inhibition of the
morphine-induced rewarding effect by the direct activation of spinal
protein kinase C in mice
62
Introduction
   Several clinical studies have suggested that in only a few cases can psychological
dependence on opioids be considered to be a serious side-effect, when patients suffer
from severe pain. Previously, it has been demonstrated that morphine failed to induce
a rewarding effect in rodents under a chronic pain-like state es'67"OD. The mesolimbic
dopaminergic system, which projects from the VTA of the midbrain to the N.Acc., has
been identified as the critical substrate of the rewarding effect of morphine i08"op). It
has been reported that inflammatory nociception activated endogenous K-opioidergic
systems to decrease dopamine release in the brain, resulting in suppression of the
morphine-induced rewarding effect 6D. In contrast, sciatic nerve ligation suppressed
morphine-induced dopamine release in the N.Acc., and this was associated with the
inhibition of pt-opioid receptor-mediated G-protein activation in the VTA 65). These
findings strongly support the idea that a chronic pain-like state may lead to a change in
the endogenous opioidergic system linked to the reward circuit. Interestingly, a s.c.
morphine-induced place preference was significantly suppressed by a single j.t.
pretreatment with PDBu 28). Accordingly, activation of PKC in the spinal cord
contributes to the attenuation of the morphine-induced rewarding effect through an
increase in the sensitivity of spinal cord neuronal responses to excitatory inputs. In
Chapter 2, I performed that activation of spinal PKCy lead to the activation of ascending
pain transmission, resulting in the increase in the activity of several brain regions
including mesolimbic dopaminergic system.
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   Therefore, I hypothesized that activation of PKC in the spinal cord could lead to
changes in the endogenous opioidergic system, thereby contributing to attenuation of
the morphine-induced rewarding effect. The aim of present study was to investigate
the role of an endogenous pt-opioid peptide 6-endorphin in hyperalgesia and suppression
of the morphine-induced rewarding effect by the PDBu-induced activation of PKC in
the spinal cord using P-endorphin knockout mice.
M
                         Materials and methods
Animals
   In the present Chapter, I used the male and female 6-endorphin peptides derived
from propiomelanocortin (Pomc) gene-knockout mice (The Jackson Laboratory, Bar
Harbor, ME, USA), which were C57BL16J and 129S2/SvPas mixed genetic background
as described previously by Rubinstein et al. "O). Animals were housed in a room
maintained at 23 Å} 1 eC with a 12 hr lightidark cycle (light on 8:OO A.M. to 8:OO
P.M.). Food and water were available ad libitum.
Genotyping
   The genotype of offspring from P-endorphin knockout (-1-) mice (The Jackson
Laboratory, Bar Harbor, ME, USA) was determined by polymerase chain reaction
(PCR) using ear DNA obtained from pentobarbha1 (70 mg/kg, i.p.)-anesthetized mice.
PCR analysis was performed using a BD Advantage'M-GC 2 PCR kit (BD Biosciences
Clontech, Palo Alto, CA, USA), according to the manufacturer's instructions, with the
extracted DNA template (10 nglpL) and synthesized POMC primers: a sense primer of
POMC (5'-- GAA GTA CGT CAT GGG TCA CT -3'), an antisense primer of POMC
(5'- GCT GGG GCA AGG AGG TTG AGA -3') and an antisense primer of
phosphoglycerate kinase (5'-GGGAACTTC(rrGACrAG GGG -3') "'), which includes
a neo expression cassette inserted into a deleted exon 3 of the POMC gene 'iO). PCR
products generated using the primers of antisense phospho-glycerate kinase and sense
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POMC revealed a single band of 850-900 base pairs (bp) (targeted deficient allele), and
those generated using the primers of antisense POMC and sense POMC revealed a
single band of 750--800 bp (wild-type allele). Briefly, a point mutation was introduced
by site-directed mutagenesis into exon 3 of the POMC gene to generate a premature
translational stop codon. The resultant truncated prohormone lacks the
carboxyl-terminal 31 amino acids in 6-endorphin, but is expressed at normal levels and
is correctly processed into adrenocorticotropic hormone, melanocyte-stimulating
hormones and gamma-lipotropic hormone.
Intrathecal (i.t) injection
   Intrathecal (i.t.) injection was performed following the method described in Chapter
1.
Measurement of thermal hyperalgesia
   Thermal hyperalgesia was measured following the method described in Chapter 1.
Place conditioning
   Place conditioning was conducted as described previously 'i2). The apparatus was
a shuttle box (15 cm wide Å~ 30 cm Iong Å~ 15 cm high) that was made of acrylic
resin board and divided into two equal-sized compartments. One compartment was
white with a textured floor, and the other was black with a smooth floor to create
equally preferable compartments. The place conditioning schedule consisted of three
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phases (preconditioning test, conditioning, and postconditioning test). The
preconditioning test was performed as follows: the partition separating the two
compartments was raised to 7 cm above the floor, a neutral platform was inserted along
the seam separating the compartments, and anima}s that had not been treated with either
drugs or saline were then placed on the platform. The time spent in each compartment
during a 9oo sec session was then recorded automatically with an infrared beam sensor
(KN-80; Natsume Seisakusyo, Tokyo, Japan). Conditioning sessions (3 days for
morphine, 3 days for saline) were conducted once daily for 6 days. Immediately after s.c.
injection of morphine (5mg/kg), these animals were placed in the opposite compartment
to that in which they had spent the most time in the pre-conditioning test for 1 hr. On
alternative days, these animals received saline and were placed in the other
compartment for 1 hr. On the day after the final conditioning session, a postconditioning
test that was identical to the preconditioning test was performed.
Pain-like behaviors
   Groups of mice were placed individually in an observation cage (10Å~ 17 Å~ 11 cm;
width Å~ length Å~ height) immediately after i.t. injection of PDBu (10 nmollmouse) or
vehicle (109o DMSO in saline). The number of scratching and licking or biting
behaviors was counted, and the duration of scratching and licking or biting behaviors
was measured for 20 min after i.t. injection. In addition, the expression of severe
tail-shaking and spontaneous or touch-evoked vocalization was checked for 20 min after
i.t. injection. Each group consisted of 10 mice per vehicle or PDBu (10 nmol! mouse)
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treatment. All behavioral experiments were conducted in a single-blind fashion to
avoid the effect of subjectivity.
Drugs
   The drugs used in the present study were the specific PKC activator PDBu (Sigma
Co., St Louis, Mo., USA) and morphine (Daiichi - Sankyo Co., Tokyo, Japan). PDBu
was dissolved in 109o DMSO containing O.99o saline, respectively. Morphine was
dissolved in O.99e saline.
Statistical data analysis
   The data are presented as the mean Å} S.E.M. The statistical significance of
differences between the groups was assessed by one-way analysis of variance
(ANOVA) followed by the Bonferroni/Dunnett test or by Student's t-test. Fisher's
exact probability test was used to compare two groups for a positive response.
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Results
   The genotype of offspring from B-endorphin knockout (-1-) mice was confirmed by
PCR analysis using DNA extracted from the ear. As shown in Fig. 3-IA ( lanes 1 and 2),
P-endorphin knockout (-1-) mice yielded a targeted deficient allele single amplification
product. In contrast, 6-endorphin (+/+) (wild-type) mice showed a single amplification
product (Fig. 3-IA, lanes 3 and 4).
   Using these genotype mice, I investigated whether the PKC activator PDBu could
affect the latency of paw withdrawal from a thermal stimulus at 24 hr after i.t. injection
of PDBu. No differences in the response thresholds were noted before i.t. injection of
vehicle or PDBu (Fig. 3-IB). The latency of paw withdrawal from a thermal
stimulus was significantly decreased in PDBu--treated wild-type and P-endorphin
knockout (-/-) mice (wild-PDBu-treated mice: 6.2 Å} O.2 sec, ***pÅqO.OOI vs.
wild-vehicle-treated mice; 6-endorphin knockout (-!-)-PDBu-treated mice: 5.7 Å} O.3
sec, ###pÅqO.OOI vs. 6-endorphin knockout (-/-)-vehicle-treated mice, Fig. 3-IC)
compared with that in vehicle-treated mice (wild-vehicle-treated mice: 9.7 Å} O.3 sec;
P-endorphin knockout (-1-)-vehicle-treated mice: 9.6 Å} O.2 sec). Furthermore, a
significant decrease in the latency of paw withdrawal from a thermal stimulus lasted for
at least 9 days after i.t injection of PDBu (on day 9, wild-PDBu-treated mice: 6.3 Å} O.2
sec, "** p ÅqO.OOI vs. wild-vehicle-treated mice: 10.0 Å} O.3 sec,P-endorphin
knockout-PDBu-treated mice: 6.1 Å} O.2 sec, ###p ÅqO.OOI vs. P-endorphin
knockout-vehicle-treated mice; 9.5 Å} O.2 sec, Fig. 3-ID). However, these were no
                                  69
significant changes in the response thresholds between wild-type and P-endorphin
knockout mice.
   In the present study, I also observed pain-like behaviors induced by i.t. injection of
PDBu in wild-type or P-endorphin knockout mice. PDBu (10 nmol/mouse) given i.t.
produced dramatic scratching and Iicking or biting behaviors in mice with both
genotypes (Table 3-1). These PDBu-induced scratching and licking and biting
behaviors started about iF5 min after i.t. injection and lasted for approximately 60 min.
Control mice that were injected i.t. with vehicle (109o DMSO in saline) did not show
these behaviors (Table 3-1). Furthermore, other aversive behaviors such as severe
tail-shaking and vocalization were also observed after i.t. administration of PDBu
(Table 3-1). However, there were no significant differences in pain-like behaviors
between wild-type and P-endorphin knockout mice.
   Recently, it has been reported that activated PKC in the spinal cord under chronic
pain-like hyperalgesia may play a substantial role in the suppression of the
morphine-induced rewarding effect in mice with chronic pain-like hyperalgesia i'3).
Therefore, I next investigated whether P-endorphin could be involved in the suppression
of the morphine-induced rewarding effect by i.t. pretreatment with PDBu using
P-endorphin knockout (-1-) mice. The s.c. injection of morphine (5 mg/kg) produced
a significant place preference in mice of both genotypes that had been pretreated i.t.
with vehicle (***pÅqO.OOI vs. wild-type or **pÅqO.Ol vs. P-endorphin knockout with i.t.
vehicle plus s.c. saline group). A single i.t. pretreatment with PDBu (10 nmollmouse)
in wild-type mice caused a significant suppression of the morphine-induced place
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preference (##pÅqO.Ol; wild-type with i.t. vehicle plus s.c. morphine group vs. wild-type
with i.t. PDBu (10 nmollmouse) plus s.c. morphine group, Fig. 3-2). In contrast, the
place preference induced by morphine at 5 mglkg (s.c.) was not suppressed in
P-endorphin knockout (-/-) mice with a single i.t. pretreatment of PDBu at 10 nmol
(Fig. 3-2).
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Fig. 3-1
   Effect of a single (i.t.) injection of the PKC activator PDBu on the latency of paw withdrawal
from a thermal stimulus in wild-type (+/+) and 6-endorphin knockout (-1-) mice. (A)
Representative PCR for using propiomelanocortin (Pomc) DNA extracted from the ear of either
wild-type (+1+) or 6-endorphin knockout (-1-) mice. While S-endorphin knockout (-/-) yielded
a targeted deficient allele single amplification product (lanes 1 and 2), wild-type mice showed a
wild-type allele single amplification products (lanes 3 and 4). The latency of paw withdrawal
from a thermal stimulus was measured at (B) O, (C) 1, and (D) 9 days after i.t. injection of
vehicle or PDBu (10 nmollmouse). Each column represents the mean with SEM of 9-10 mice.
"*" pÅqO.OOI vs. wild-type i.t vehicle group, ###pÅqO.OOI vs. 6-endorphin knockout i.t. yehic]e
group.
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Pain-like behaviors induced by i.t. in.iection of PDBu in P-endorphin (-/-) mice
Ayersiye behavior
Wild-type (+1+) P-endorphin (-/-)
Vehicle PDBu Vehicle PDBu
Scratching(År10 times) OllO 5/10
**
ol1e 6flO
##
*
Scratching(År1 min) O/lO 4/1O Ol1O 3/10
Licking or biting ÅqÅrle times) y{o gtlo *** 2flO 8tlO ###
Licking or biting (År1 m;n) OllO 911O
**ij
Ol1O 8/IO
###
Seyere tail-shaking O/1O lO/10
***
Of1O 7/1O
##
Vocalization O/IO 6flO
**
Of1O 411O
#
Table 3-1
Groups were wild-type mice treated i.L with PDBu (1O nmol/mouse) or vehicle (109o DMSO in
saline) and 6-endorphin knockout (-/-) mice treated i.t. with PDBu (10 nmollmouse) or vehicle
(109o DMSO in saline). Immediately after i.t. injection, the number of scratching and licking or
biting behaviors was counted and the duration of scratching and licking or biting behaviors was
measured for 20 min after i.t injection of PDBu. In addition, the expression of seyere tail
shaking and spontaneous or touch-evoked vocalization was checked for 20 min after the i.t.
injection of PDBu. The term `positive animal' refers to animals that exhibited a certain number
of positive responses (År10 times) or showed a threshold total duration of responses (År1 min).
*pÅqO.05, *"pÅqO.Ol and ***pÅqO.OOI vs. wild-type i.t vehicle group. #pÅqO.05, ##pÅqO.Ol and
###pÅqO.OOI vs. 6-endorphin knockout i.t. vehicle group.
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Fig. 3-2
   Effects of a single l.t. injection of PDBu on the morphine-induced place preference in
wild-type (-}-/+) ancl fi-efidorphiR knockolit (V-) mice. ConditloniRg sessions (three for
morphine, three for saline) were started the day after i.t,. injection of PDBu (le Rmoilmotise) or
vehicle alld conducted once daily fer 6 days. Emmediately after each s.c. Injection of morphine
(5 mgfkg) or saline, the mouse was placed and conditioned ln either compartment for l hr. On
the day after the flnal cenditioning sesslon, a pest-coBditioning test that was ideRticai to the
pre-condltioning test was performed. "Irhe ordinate shows mean differences between times
spent in the morphine-paired and saline-paired sSdes of the test box. The data represent the
mean with SEM of 7-IO rrtice. **pÅqO.Ol and "**pÅqO.OOI vs. wild-type i.L vehicle plus s.c.
saline group. ##pÅqO.Ol vs. svild-type i.t. vehicle plus s.c. inorphine group. $pÅqO.05 vs. xvild-•type
i.L PDBu plus s.c. morphlne group.
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Discussion
   Recent studies have provided evidence that PKC expressed on dorsal horn neurons
plays an important role in regulating pain hypersensitivity in several different pain
models 3i•89•`i`•'iS. The activation of PKC in the dorsal horn of the spinal cord may be
responsible for the release of excitatory amino acids and neuropeptides, resulting in the
initiation of central sensitization. It was documented that thermal hyperalgesia induced
by sciatic nerve ligation was markedly suppressed by repeated i.t. pretreatment with a
selective PKC inhibitor ii6). It was also found that the level of membrane-bound PKCy
isoform, which is identified in neurons of the brain and the inner part of laminae II of the
spinal cord, was significantly increased on the ipsilateral side of the spinal cord in sciatic
nerve-ligated mice iO'). Interestingly, mice that lack the PKCy isoform exhibit normal
responses to acute pain stimuli, but also show an almost complete lack of development of
neuropathic pain-like behaviors after sciatic nerve ligation 30'3'). Collectively, these findings
provide further evidence that the activation of neuronal cPKC in the dorsal horn of the
spinal cord by nerve injury may play a key role in the development of a neuropathic
pain-like state in mice.
   The key finding of the present study was that suppression of the morphine-induced
rewarding effect by i.t. injection of PDBu was abolished in P-endorphin knockout mice.
Previously it has been demonstrated that a single i.t. injection of PDBu caused a
 dramatic suppression of the morphine-induced place preference 28). Nociceptive
 information is thought to be transmitted by neuronal pathways projecting from the
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thalamus to various brain regions, including the VTA, which possesses high densities of
p-opioid receptors and plays a critical role in psychological dependence on p-opioid
receptor agonists such as morphine. Interestingly, it has been reported that sciatic
nerve injury leads to a reduction in pt-opioidergic function in the VTA, resulting in the
suppression of morphine-induced dopamine release in the N.Acc., which is terminus of
the mesolimbic dopaminergic neurons 6S.
   Based on these findings, the direct activation of PKC in the spinal cord could lead to
an increase in the release of P-endorphin in the brain. This phenomenon may eventually
cause a reduction in pt-opioid receptor function in the VTA, resulting in suppression of
the morphine-induced rewarding effect under a neuropathic pain-like state.
   In the present study, there were no differences in the response to thermal stimuli or
pain-like behavior induced by i.t. PDBu between wild-type and P-endorphin knockout
mice. In contrast, the direct activation of PKC by i.t. PDBu in the spinal cord
eliminated the suppression of the morphine-induced place preference following sciatic
nerve ligation in B-endorphin knockout mice. Although further study is required, it is
possible that the release of P-endorphin by the activation of PKC in the spinal cord can
regulate the affective-motivational component of pain, which includes mesolimbic
dopaminergic transmission, but not the sensory-discriminative component of pain.
This hypothesis can be supported by the recent finding that sciatic nerve ligation causes
a reduction in p-opioid receptor function with an increase in the level of
membrane-bound G-protein-coupled kinase 2, which can mediate the desensitization of
pt-opioid receptors. This phenomenon was observed in the VTA but not in the
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thalamus, PAG or ponslmedulla 66•ii').
   In conclusion, I have demonstrated that deletion of the P-endorphin gene reversed
the suppression of the morphine-induced place preference by the activation of spinal
PKC by i.t. PDBu treatment in mice. These findings provide further evidence that a
neuropathic pain-like state caused by the direct activation of PKC in the spinal cord
leads to the constant release of P-endorphin at the supraspinal level, resulting in the
suppression of psychological dependence on opioids.
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Chapter 4
Direct evidence for the involvement of endogenous P-endorphin in the
suppression of the morphine-induced rewarding effect under a
neuropathic pain-like state
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Introduction
   The mesolimbic dopamine system, which consists of dopaminergic neurons in the
VTA and their projections to the N.Acc, has been implicated in the rewarding properties
of opioids 'os). Especially, pt-opioid receptors located in the VTA have been shown to
be critical for opioid reward ii8'i'9). Injection of the specific pt-opioid receptor agonist
DAMGO into the VTA, but not the N.Acc., produced a significant place preference in
the rat i08).
  When a patient is an appropriate candidate for an opioid but the drug is not available
in a sufficient dose to allow the patient to function adequately and maintain a reasonable
lifestyle, it has often been proposed that opioid addiction does not arise as a
consequence of the treatment of pain with opioid. In fact, this argument has been used
to support the safe use of opioid for the treatment of severe pain 6"62). Although many
clinical studies have demonstrated that when opioid analgesics including morphine are
used to control pain, psychological dependence is not a major concern i20), the scientific
support for this clinical experience is still needed if physicians are to be confident in
using adequate doses of opioids for the treatment of severe pain.
  Previously, it has been reported that morphine failed to induce rewarding effects in
rodents under formalin injection 63'67'69) and sciatic nerve ligation es'66'i07). In addition,
sciatic nerve ligation suppressed the morphine-induced dopamine release in the N.Acc.
associated with the inhibition of p-opioid receptor-mediated G-protein activation in the
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VTA 66). These findings suggest that the dysfunction of p-opioid receptor in the VTA
may be responsible for the suppression of morphine dependence under a chronic pain.
   P-Endorphin is an endogenous opioid peptide that has a profound analgesic effect
when administered to the central nervous system i2i'i22). The acute release of
P-endorphin into ventricular CSF has been demonstrated during electrical stimulation of
the periaqueductal grey matter in humans, and a relation has been found between
analgesia and P-endorphin release i"). While most studies on patients with chronic
pain have found no differences in CSF P-endorphin concentrations, a few have shown
decreased P-endorphin concentrations during chronic pain. Therefore, there is no firm
evidence obtained from measuring P-endorphin in human CSF that the presence of
chronic pain in general is associated with altered activity in 6-endorphin neurons. In
rodents, P-endorphin levels have been found to be increased in the rat hypothalamus,
periaqueductal grey matter and posteromedial thalamus under formalin-induced pain
'2`'26). Furthermore, it has been reported that pain induces the release of endogenous
opioid peptides in the brain, including the mesolimbic area in humans '27). Therefore, I
proposed that sciatic nerve injury may increase the release of endogenous opioid
peptides that interact with pt-opioid receptors in the mesolimbic area, and in turn cause
the down-regulation of pt--opioid receptor in this region.
   Many lines of evidence support the notion that the activation of spinal PKC is
closely related to the development or maintenance of neuropathic pain. In Chapter 3, I
found that released P-endorphin is likely to be responsible for the development of the
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suppression of morphine-induced rewarding effect following a direct activation of
spinal PKCy.
   Knockout mice with 6-endorphin gene deletions have been successfully developed
by homologous recombination i28). Transgenic 6-endorphin kBockout mice allow us to
determine physiological functions mediated via central P-endorphin-containing fibers
under a chronic pain-like state. The aim of the present study was to further investigate
the molecular mechanisms that underlie the suppression of the opioid-induced
rewarding effect under a neuropathic pain-like state using 6-endorphin knockout mice.
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Materials and Methods
Animals
   As described in Chapter 3, I used the male and female P-endorphin peptides derived
from proopiomelanocortin (Pomc) gene-knockout mice (The Jackson Laboratory, Bar
Harbor, ME, USA) and male Sprague-Dawley rats (Tokyo Laboratory Animals Science
Co., Ltd, Tokyo, Japan). Animals were housed in a room maintained at 23 Å} 1 OC
with a 12 hr lightidark cycle (light on 8:OO A.M. to 8:OO P.M.). Food and water were
available ad libitum.
Genotyping
   The procedure for
Chapter 3.
genotyplng was performed following the method described in
Surgery and microinjection
   After 3 days of habituation to the main animal colony, all rats were anesthetized
with sodium pentobarbital (50 mg/kg, i.p.). The anesthetized animals were placed in a
stereotaxic apparatus. The sku!1 was exposed, and a small hole was made using a
dental drill. A guide cannula (AG-9; Eicom, Kyoto, Japan) was implanted into the
VTA (from bregma: posterior, 5.3 mm; lateral, O.9 mm; ventral, 7.7 mm) according to
the atlas of Paxinos and Watson (1998) i29). The guide cannula was fixed to the skull
with cranioplastic cement. Three to five days after surgery, the animals were injected
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with P-endorphin antibody (1:500 or 1:10oo) (Peninsula Laboratories Inc., CA) diluted
in saline or saline alone in a volume of O.3 psL/rat into the VTA 10 min before the start
of nerve injury and once a day for 3 consecutive days after nerve injury. In the
microinjection method, I used an injection cannula (AMI-9.5; Eicom) that extended
beyond the guide cannula by O.5 mm. A stainless steel injection cannula was inserted
into the guide cannula for each animal. The injection cannula was connected through
polyethylene tubing to a 10 ptL Hamilton syringe that was preloaded with P-endorphin
antibody or saline, which was delivered by a motorized syringe pump in a volume of O.3
ptL over 60 sec.
Neuropathic pain model
   The rats and mice were deeply anesthetized with isoflurane. A partial sciatic nerve
injury by tying a tight ligature with a 8-O silk suture around approximately one-third to
one-half the diameter of the sciatic nerve on the right side (ipsilateral side) under a light
microscope (SD30, OIympus, Tokyo, Japan) as described previously i30•i3'). In
sham-operated animals, the nerve was exposed without Iigation.
Place conditioning
   Place conditioning was conducted as described previously i'2). The apparatus was a
shuttle box (mouse size, 15 cm wide Å~ 30 cm long Å~ l5 cm high; rat size, 30 cm
wide Å~ 60 cm long Å~ 30 cm high) that was made of acrylic resin board and divided
into two equal-sized compartments. One compartment was white with a textured floor,
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and the other was black with a smooth floor to create equally preferable compartments.
The place conditioning schedule consisted of three phases (preconditioning test,
conditioning, and postconditioning test). The preconditioning test was performed as
follows: the partition separating the two compartments was raised to 7 cm (mouse) or
12 cm (rat) above the fioor, a neutral platform was inserted along the seam separating
the compartments, and animals that had not been treated with either drugs or saline were
then placed on the platform. The time spent in each compartment during a 900 sec
session was then recorded automatically with an infrared beam sensor (KN-80; Natsume
Seisakusyo, Tokyo, Japan). Conditioning sessions (3 days for DAMGO (Sigma Co.,
St Louis, MO, USA) (rats) or morphine (mice), 3 days for saline) were conducted once
daily for 6 days. Immediately after the microinjection of DAMGO into the VTA (rats)
or s.c. injection of morphine (5mg/kg) (mice), these animals were placed in the
compartment opposite that in which they had spent the most time in the
pre-conditioning test for 1 hr. On alternative days, these animals received saline and
were placed in the other compartment for 1 hr. On the day after the final conditioning
session, a postconditioning test that was identical to the preconditioning test was
performed.
Measurement of thermal hyperalgesia
   To assess the sensitivity to thermal stimulation, each of the hind paws of rats were
tested individually using a thermal stimulus apparatus (model 33 Analgesia Meter; IITC
Inc./ Life Science Instruments, Woodland Hills, CA, USA). The intensity of the
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thermal stimulus was adjusted to achieve an average baseline paw withdrawal latency of
approximately 8 to 10 sec in naive rats. Only quick hind paw movements (with or
without licking of the hind paws) away from the stimulus were considered to be a
withdrawal response. Paw movements associated with locomotion or weight shifting
were not counted as a response. The paws were measured alternating between the left
and right with an interval of more than 3 min between measurements. The latency of
paw withdrawal after the thermal stimulus was determined as the average of three
measurements per paw.
Injections of retrograde marker fluoro-gold
   To identify mesolimbic projecting neurons, the retrograde tracer fluoro-gold (FG)
(49o, Fluorochrome, Englewood, CO) was injected into the N.Acc. First, rats were
deeply anesthetized with isoflurane. The anesthetized animals were placed in a
stereotaxic apparatus. The skull was exposed, and double holes were drilled through
the skull over the N.Acc. (AP: +1.5 mm, ML: -O.5 mm, DV: -7.0 mm) according to the
atlas of Paxinos and Watson (l998) '29). The skull was exposed, and a small hole was
made using a dental drill. A micropipette with a diameter of about 15-20 ptm was
filled with FG solution. FG was pressure-injected (200 nL) into the N.Acc. of the right
hemisphere. After the injection, the micropipette was left in place for 5 min to avoid
leakage after removal of the injection cannula. Following surgery, the scalp was
closed. Three days after FG injection, rats were re-anesthetized with isoflurane and
subjected to surgery for partial nerve injury.
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Sample preparation
   Ten days after nerve ligation, rats were deeply anesthetized with isoflurane and
intracardially perfusion-fixed with freshly prepared 4 9o paraformaldehyde in O.1 M
phosphate-buffered saline (PBS, pH 7.4). After perfusion, the brains were then
quickly removed, and thick coronal sections of the midbrain including the VTA was
initially dissected using Brain Blocker was quickly removed. These sections were
post-fixed in 4 9o paraformaldehyde for 3 hr, and permeated with 20 9o sucrose in O. IM
PBS for 1 day and 30 9o sucrose in O.IM PBS for 2 days with agitation. They were
then frozen in an embedding compound (Sakura Finetechnical, Tokyo, Japan) on
isopentane using liquid nitrogen and stored at -30 Åé until use. Frozen these sections
were cut with a freezing cryostat (Leica CM 1510, Leica Microsystems AG, Wetzlar,
Germany) at a thickness of 8 mm and thaw-mounted on poly-L-lysine-coated glass
slides.
Immunohistochemistry
   The brain sections were blocked in 10 9o nomial goat serum (NGS) in O.OIM PBS
for 1 hr at room temperature. The primary antibody [1:400 phosphorylated-tyrosine
hydroxylase (Ser31) (Chemicon International, Inc., CA, USA)] was diluted in O.Ol M
PBS containing 10 9o NGS and incubated for 2 nights at 4 OC. The samples were then
rinsed and incubated with an appropriate secondary antibody conjugated with Alexa 488
for 2 hr at room temperature. Since the staining intensity might vary between
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experiments, control sections were included in each run of staining. The slides were
then cover-slipped with PermaFluor Aqueous mounting medium (ImmunonTM;
ThermoShandon, Pittsburgh, PA, USA). Fluorescence of FG and immunolabeling
were detected using a light microscope (Olympus BX-80; Olympus) and photographed
with a digital camera (CoolSNAP HQ; Olympus). Fluorescence immunolabeling was
detected using a U-MNIBA filter cube (Olympus, Tokyo, Japan). The distribution of
gold-emitting FG retrogradely-labeled neurons and FG injection sites was determined
using a microscope (Olympus BX-60; Olympus). The fluorescence of FG was
observed with a filter (excitationlemission peaks, 3231408 nm).
 [35s]GTPyS binding assay
   For membrane preparation, the mouse a section of the lower midbrain that included
the VTA and limbic forebrain that included the N.Acc, as described previously '32), were
quickly removed after decapitation, and rapidly transferred to a tube filled with ice-cold
buffer. The membrane homogenate (3-8 ptg proteinlassay) was prepared as described
previously '33) and incubated at 250C for 2 hr in lmL of assay buffer with various
concentrations of each agonist, 30 ptM GDP and 50pM [35S]GTPyS (specific activity,
1000 Cilmmol; Amersham, Arlington Heights, IL, USA). The reaction was terminated
by filtration using Whatman GF/B glass filters (Brandel, Gaithersburg, MD, USA) that
had been presoaked in 50 pM Tris-HCI, pH 7.4, and 5 ptM MgCl, at 40C for 2 hr. The
filters were washed three times with 5 mL of ice-cold Tris-HCI buffer, pH 7.4, and then
transferred to scintillation-counting vials containing 3 mL of Clear--sol II (Nacalai
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Tesque Inc., Kyoto, JAPAN) and equilibrated for l2 hr. The radioactivity in the samples
was determined with a liquid scintillation analyzer. Nonspecific binding was measured
in the presence of 10 ptM unlabeled GTPyS. In the present study, sample preparation
was performed 10 days after partial sciatic nerve-ligation.
Mouse in vivo microdialysis study and quantification of dopamine
   Stereotaxic surgery was performed under sodium pentobarbital (70 mg/kg, i.p.)
anesthesia. Mice were placed in a stereotaxic apparatus, and the skull was exposed. A
small hole was then made using a dental drill. A microdialysis probe (D-I-6-Ol;
lmmmembrane length; Eicom) was implanted into the N.Acc. (from bregma: anterior,
+1.5 mm; lateral, +O.9 mm; ventral,-4.9 mm) according to the atlas of Paxinos and
Franklin (1997) '05). The microdialysis probe was fixed to the skull with cranioplastic
cement. At 24 hr after implantation, mice were placed in the experimental cages (30
cm wide Å~ 30 cm long Å~ 30 cm high). The probe was perfused continuously at a
flow rate of 2 ptLlmin with aCSF containing O.9 mM MgCl,, 147.0 mM NaCl, 4.0 mM
KCI, and 1.2 mM CaCl,. Outflow fractions were taken every 5 min. After 15
baseline fractions were collected, mice were given morphine (10 mg/kg, s.c.) or saline
(1 mL/kg, s.c.). For this experiment, dialysis samples were collected for 180 min after
morphine or saline treatment. Dialysis fractions were then analyzed using HPLC with
ECD (HTEC-500; Eicom). Dopamine was separated by a column with a mobile phase
containing O.1 M NaH2P04, O.l M Na,HPO,, 2.0 mM sodium 1-decane sulfonate,
O.lmM EDTA (2Na), and 19o methanol. The mobile phase was delivered at a flow
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rate of 550 ptL/min. Dopamine was identified according to the retention times of a
dopamine standard, and amounts of dopamine were quantified by calculating with peak
areas. The baseline microdialysis data were calculated as concentrations in the
dialysates. Other microdialysis data are expressed as percentages of the corresponding
baseline level.
Drugs
   The drug used in the present study were morphine (Daiichi-Sankyo Co., Tokyo,
Japan) and DAMGO (Sigma Co., St Louis, Mo., USA). Morphine and DAMGO were
dissolved in O.9qo saline.
Statistical data analysis
   The data are presented as the mean Å} S.E.M. The statistical significance of
differences between the groups was assessed by one- or two-way ANOVA followed by
the Bonferroni/Dunnett test or by Student's t-test.
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Results
Thermal hyperalgesia induced by sciatic nerve ligation in rats
   First, I confirmed that sciatic nerve-ligated rats exhibited a significant and persistent
decrease in the latency of paw-withdrawal on the ipsilateral side, indicating a
neuropathic pain-like state (Fig. 4-1). Since the withdrawal latencies of the ipsilateral
paw in response to a thermal stimulus were maximally decreased at 4 days after sciatic
nerve ligation (Day 4: sham-ipsilateral vs. Iigation-ipsilateral, pÅqO.OOI), these animals
were used for behavioral and biochemical studies.
Effect of intra-VTA injection of P-endorphin antibody on suppression of the
DAMGO-induced place preference by sciatic nerve ligation in rats
   Under these conditions, I investigated whether sciatic nerve ligation could affect the
place conditioning induced by the selective pt-opioid receptor agonist DAMGO in rats.
It has been reported that intra-VTA administration of DAMGO caused a
dose-dependent preference for the drug-associated place in mice i08). In the present
study, I also demonstrated that the microinjection of DAMGO at 1 nmol into the VTA
produced a significant preference for the drug-associated place in sham-operated rats
(pÅqO.05 vs. sham-saline groups) (Fig. 4-2). In contrast, the DAMGO-induced place
preference was significantly suppressed in sciatic nerve-ligated rats (pÅqO.05 vs.
sham-DAMGO groups). In contrast, microinjection of P-endorphin antibody into the
VTA just before and after 3 days of sciatic nerve-ligation significantly reversed the
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suppresslon
(pÅqO.Ol vs.
of DAMGO-induced place preference in
saline-ligation--DAMGO groups).
rats with sciatic nerve ligation
Effect of sciatic nerve ligation on the activity of the mesolimbic dopamine system in
rats
   To investigate a possible change in tyrosine hydroxylase activity in the VTA of
sciatic nerve-ligated rats, immunohistochemical studies were performed. As shown in
Fig. 18, p-TH (Ser31) immunoreactivity was prominently observed in the VTA of
sham-operated rats (Fig. 4-3A and D: high magnification). Sciatic nerve ligation
dramatically diminished the p-TH immunoreactivity in this region (Fig. 43B).
Consistent with many previous studies which have characterized afferent projections to
the N.Acc., FG-containing cells were apparently detected in the VTA after
microinjection of the retrograde tracer FG into the shell region of the unilateral N.Acc.
(Fig. 4-3C). Further immunostaining showed that a population of retrogradely labeled
neurons in the VTA was also immunoreactive for p-TH (Ser3 1) (Fig.4-3E).
Effect of deletion of the P-endorphin gene on the suppression of morphine reward
by sciatic nerve ligation in mice
   The genotype of offspring from 6-endorphin knockout (-1-) mice was confirmed by
PCR analysis using DNA extracted from the ear. As shown in Fig. 44A (lanes 3 and 4),
B-endorphin knockout (-/-) mice yielded a targeted deficient allele single amplification
product. In contrast, P-endorphin (+1+) (wild-type) mice showed a single amplification
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product (Fig. 4-4A, lanes 1 and 2). Using these genotype mice, I performed a
conditioned place preference test. In wild-type mice, the morphine-conditioned place
preference was significantly attenuated following sciatic nerve ligation. (pÅqO.05 vs.
sham-wild-type-morphine; Fig. 4-4B). In contrast, there were no significant changes in
the morphine-induced place preference between sham- and nerve-ligated P-endorphin
knockout (-1-) mice (Fig. 4-4B), indicating that suppression of the morphine-induced
rewarding effect in sciatic nerve Iigation was abolished by absence of the B-endorphin
gene.
Effect of the deletion of P-endorphin gene on the down-regulation of p-opioid
receptor function in the VTA of mice with sciatic nerve ligation
   The ability of DAMGO to activate pt-opioid receptor linked to its G-proteins in the
lower midbrain including the VTA obtained from sham-operated or sciatic nerve-ligated
wild-type and P-endorphin knockout (-1-) mice was examined by monitoring the binding
of [35S]GTPyS. DAMGO (10'8-10-5 M) produced a concentration-dependent increase
in the binding of [35S]GTPyS to lower midbrain membranes in sham-operated mice.
Conversely, the level of [35S]GTPyS binding to this area stimulated by DAMGO in
nerve--ligated wild-type mice was significantly lower than that observed in
sham-operated wild-type mice (Fig. 4-5A, 10-5 M; pÅqO.Ol vs. sham-operated wild-type
group). In contrast, there were no significant changes in the DAMGO-induced increase
in the binding of [35S]GTPyS to lower midbrain membranes between nerve-ligated
92
P-endorphin knockout (-1-) mice and sham-operated 6-endorphin knockout (-1-)
mice (Fig.4-5B).
   Since it has been demonstrated that activation of the mesolimbic dopamine system
is critically linked to the expression of the rewarding effects of morphine, I examined
whether the suppression of the rewarding effect induced by morphine after nerve injury
could result from changes in dopamine receptor functioB linked to G-proteins in the
N.Acc. (Fig. 4-6). The ability of dopamine to activate G--proteins in the N.Acc. of
sham-operated and sciatic nerve-ligated mice was examined by monitoring the binding
of (35S]GTPyS to N.Acc. membranes. dopamine (10"8-10'5 M) produced a
concentration-dependent increase in [35S]6TPyS binding to N.Acc. membranes from
both sham-operated and sciatic nerve-Iigated wild-type mice to the same degree (Fig.
4--6A). Similarly, no differences in the increase in [35S]GTPyS binding stimulated by
dopamine were noted between sham-operated and sciatic nerve-ligated P-endorphin
knockout (-/-) mice (Fig. 46B).
Changes in the increase in the dialysate dopamine level induced by morphine in
sciatic nerve-ligated P-endorphin knockout mice
   Fig. 4-7A shows the location of microdialysis probes within the mouse N.Acc.
Probe-inserted regions were localized in the N.Acc. Only data from mice in which
probes had been accurately inserted in the N.Acc. were used for subsequent statistical
analysis. The effect of the s.c. administration of morphine on the dialysate dopamine
Ievel in the mouse N.Acc. is shown in Fig. 4-7B. The dopamine levels were markedly
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increased by s.c. injection of morphine at 10 mglkg compared with that induced by
saline treatment in sham-operated wild-type mice. Under these conditions, the
increased level of dialysate dopamine in the N.Acc. stimu}ated by morphine was
significantly decreased in sciatic nerve-ligated wild-type mice (F(1, 234) = 2.824;
pÅqO.OOOI, sham-operated wild-type mice treated with morphine vs. Iigated wild-type
mice treated with morphine). However, the increase in the level of dialysate dopamine
stimulated by morphine was not affected in sciatic nerve-ligated P-endorphin knockout
(-1-) mice.
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Fig. 4-3
   Immunofluorescent staining for phosphorylated-tyrosine hydroxylase (Ser31) (p-TH)-like
immunoreactivity (IR) in the VTA of sham-operated rats or nerve-ligated rats (A). The images
show p-TH-like IR in the VTA of nerve-ligated rats (B) or sham-operated rats (A). (C-E)
Projection from the VTA to the nucleus accumbens (N.Acc.), (C) Cells in the VTA after
microinjection of FG into the N.Acc. are shown. The cell is positive for FG. (D and E) Apparent
co-localization of p-TH (green) with fluoro-gold (blue) in the VTA. The sample was prepared IO
da)y's after nerve ligation in rats, .Scale bars = 50 ttm
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Fig. 4-4
   (A) Representative PCR for proopiomelanocortin (Pomc) DNA extracted from the ear of either
wild-tlr'pe (+/+) or 6-endorphin knockout (-1-) mice. S-Endorphin knockout (-1-) yielded a
targeted deficient ailele single amplification product (lanes 3 and 4), whereas wild-type mice
showed a wild-type allele single amplification products (lanes 1 and 2). (B) Disappearance of the
suppression of the morphine-induced place preference by sciatic-nerve ligation due to the absence
of the 6-endorphin gene. Both genotypes of mice were conditioned by saline or morphine (5
mglkg, s.c.) after sciatic-nerve ligation or sham-operation. The data represent the mean with
S.E.M. of seven to eight mice. **"pÅqO,OOI vs. Shamlwild-typelsaline group. #pÅqO.05 vs.
Shamlwild-type!morphine group. $pÅqO.05 vs. Ligation!wild-type!morphine group.
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Fig. 4-7
   Change in the increased dialysate dopamine level induced by morphine in P-endorphin
knockout (-/-) mice. (A) Localization of microdialysis probe sites in the mouse N.Acc.
Stippled lines represent regions in svhich microdialysis probes were inserted in the mouse brain.
(B) Effects of treatment svith morphine on the dialysate dopamine level in the NAcc. in sham- or
nerve-ligated wild-type and these 6-endorphin knockout (-1-) mice. Morphine (IO mglkg, s.c.)
or saline svas injected at time O. The data are expressed as percentages of the corresponding
baseline levels with S.E.M. of three to sevens mice. F(1, 234) = 2.824; pÅqO.OOOI, sham-operated
svild-type mice treated with morphine vs. sham-operated 6-endorphin knockout (-1-) mice treated
with morphine.
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                               Discussion
   Previously, it has been reported that a state of neuropathic pain significantly
suppressed the development of the rewarding effect produced by morphine in rodents,
which was associated with a significant down-regulation of p-opioid receptor function
linked to an up-regulation of membrane-bound G-protein-coupled receptor kinase 2 in
the VTA region, which possesses high densities of pt-opioid receptors 66'i3`). This
phenomenon strongly supports the clinical observation that psychological dependence
on opioids is not a major problem for patients who suffer from a neuropathic pain-like
state, including the pain associated with cancer. I proposed that a significant
down-regulation of pt-opioid receptor function in this area may result from sustained
activation of the endogenous pt-opioidergic system following nerve injury. I
considered that nerve injury may consistently increase the release of endogenous opioid
peptide that interacts with p-opioid receptors in the VTA, resulting in a reduction of
pt-opioid receptor function in this area. Several lines of evidence suggest that, in
response to pain stimulus, the endogenous p-opioid receptor agonist 6-endorphin is
released within some brain regions, including the mesolimbic area '27).
   Thus, I thought that it might be better to directly measure 6-endorphin released in
the VTA of rodents with sciatic nerve ligation. However, some major problems had to
be addressed if I were to directly prove this hypothesis. First, it was too hard to
maintain an adequate experimental condition over a week with animals fixed to a
cannula directly connected to sampling collectors. Second, the level of released
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P-endorphin was expected to be so slight that I could have no confidence in detecting its
content in the VTA area during a neuropathic pain-like state according to
radioimmunoassay. Therefore, I decided to use both in vivo behavioral and
biochemical approaches using a specific antibody to P-endorphin and P-endorphin gene
knockout mice.
   In the present study, I first confirmed that sciatic nerve ligation suppressed a place
preference induced by microinjection of the selective pt-opioid receptor agonist
DAMGO into the VTA in rats. Furthermore, I demonstrated that nerve injury reduced
both the increase in the Ievel of extracellular dopamine by s.c. morphine in the N.Acc.
of wild-type mice and the increase in [35S]GTPyS binding to membranes of VTA
obtained from wild-type mice induced by DAMGO. Moreover, p-TH (Ser31)
immunoreactivity in the rat VTA was dramatically diminished by sciatic nerve ligation,
and some of p-TH-positive neurons were directly projected to the N.Acc. These
findings provide further evidence that a neuropathic pain-like state causes a significant
reduction in the activity of a pt-opioid receptor-mediated mesolimbic dopaminergic
pathway in rodents.
  Under these conditions, an intra-VTA injection of a specific antibody to P-endorphin
reversed the suppression of the DAMGO-induced place preference by sciatic nerve
ligation in rats. To further investigate the role of P-endorphin in the suppression of
opioid reward under a neuropathic pain-like state, I next performed several experiments
using P-endorphin gene knockout mice. It has been shown that the introduction of a
stop codon in place of the tyrosine 179 codon in the proopiomelanoconin (POMC) gene
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results in mutant mice that lack P-endorphin. These P-endorphin knockout mice
exhibit normal morphine-induced analgesia. In addition, the expression of other
peptide products (e.g. ACTH and MSH) from the POMC gene is not affected in these
transgenic mice i'O). I hypothesized that the availability of these 6-endorphin knockout
mice could provide molecular evidence for the role of 6-endorphin in the suppression of
opioid reward under a neuropathic pain. Using these transgenic mice, I demonstrated
here that the suppression of a morphine-induced place preference by sciatic nerve
ligation was abolished in P-endorphin gene knockout mice, indicating that endogenous
P-endorphin is required for recovery from the suppression of opioid reward under a
neuropathic pain-like state in rodents. The present result was mostly consistent with
the recent finding by Petraschka et al. (2007) '35).
   A key finding in the present study is that the increased [35S]GTPyS binding by
DAMGO to membranes in the VTA area obtained from wild-type mice was
dramatically decreased by sciatic nerve ligation and this effect was abolished in mice
that lacked the P-endorphin gene following sciatic nerve ligation. These results
provide molecular evidence that endogenous P-endorphin corresponds to the
down-regulation of p--opioid receptor function to activate G-proteins in the VTA
following nerve injury. Therefore, I propose here that P-endorphin released by chronic
nociceptive stimuli may continuously activate pt-opioid receptors in the VTA and in turn
lead to the down-regulation of p-opioid receptor function. This phenomenon may be
directly involved in reduced opioid reward under a neuropathic pain-like state in
rodents.
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  Another key finding of the present study is that the increased extracellular dopamine
in the N.Acc. produced by s.c. treatment with morphine was diminished by sciatic nerve
ligation in wild-type mice, and this effect was also eliminated in 6-endorphin knockout
mice with sciatic nerve ligation. This result strongly supports the idea that endogenous
P-endorphin is responsible for the suppression of opioid reward linked to a mesolimbic
dopaminergic system under a neuropathic pain-like state.
   In conclusion, I demonstrated here that suppression of a p--opioid-induced place
preference by sciatic nerve ligation was abolished by microinjection of the 6-endorphin
antibody into the VTA and deletion of the P-endorphin gene. Furthermore, the
deletion of P-endorphin also eliminated the reductions in both pt-opioid receptor
function in the VTA by nerve ligation and in the activity of mesolimbic dopaminergic
transmission projecting from the VTA to the N.Acc. regulated by pt-opioid receptors in
the VTA. These findings provide further evidence that 6-endorphin released in the
VTA is a key player in regulating the dysfunction of p-opioid receptor function to
modulate opioid reward under a neuropathic pain-like state.
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General Conclusion
The above findings led to the following conclusions:
In Chapter 1:
   In the present study, I found that a PAR-1 and PDGF-A-mediated signaling pathway
within spinal cord neurons may be directly implicated in neuropathic pain after nerye
injury in mice. Thermal hyperalgesia and tactile allodynia induced by sciatic nerve
ligation were significantly suppressed by repeated i.t. injection of hirudin, which is a
specific and potent thrombin inhibitor. Furthermore, a single i.t. injection of thrombin
produced long-lasting hyperalgesia and allodynia, and these effects were also inhibited
by hirudin in normal mice. In immunohistochemical studies, increased PAR-1-like IR
in the spinal cord after nerve injury was co-localized with PKCy. In addition, thermal
hyperalgesia and tactile allodynia induced by sciatic nerve ligation were also suppressed
by repeated i.t. injection of either the PDGF a receptor (PDGFRct)/Fc chimera protein
or the PDGFR-dependent PTK inhibitor AG17. Moreover, thermal hyperalgesia and
tactile allodynia induced by thrombin in normal mice were virtually eliminated by i.t.
pretreatment with PDGFRct/Fc.
   The present data provide novel evidence that a PAR-1 and PDGF-A-mediated
signaling pathway within the spinal cord is directly involved in the development of the
neuropathic pain-like state induced by sciatic nerve ligation in mice. Furthermore, this
signal pathway may lead to PKCy activation. Such findings raise the fascinating
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possibility that the activation of up-regulated PAR-1 located on spinal dorsal horn
neurons following nerve injury may release PDGF in the spinal cord and in turn activate
PDGFRa, leading to a neuropathic pain-like state.
In Chapter2:
   The activation of spinal PKC by i.t. treatment with PDBu caused a remarkable
increase in the activity of several brain regions in wild-type mice compared with vehicle
treatment using fMRI assay. In the somatosensory cortex, lateral thalamic nuclei and
medial thalamic nuclei, which are sensory-discriminative components of pain, i.t.
injection of PDBu produced a dramatic and time-dependent iBcrease in signal intensity.
In contrast, i.t. injection of PDBu produced a delayed but significant increase in signal
intensity in the cingulate cortex, nucleus accumbens and ventral tegmental area, which
are affective-motivational components of pain. Furthermore, these effects of PDBu
were abolished in mice that lacked the PKCy gene. These results suggest that the
activation of spinal PKCy associated with the activation of ascending pain transmission
may be an important factor in chronic pain-like hyperalgesia with changes in
emotionality.
In Chapter 3:
   In the present study, I found that the activation of spinal PKC by i.t. treatment with
PDBu, a specific PKC activator, caused thermal hyperalgesia, pain-like behaviors and
suppression of the morphine-induced rewarding effect. This suppression of morphine
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reward was eliminated in mice that lacked 6-endorphin. In contrast, thermal
hyperalgesia and pain-like behaviors were not affected in P-endorphin knockout mice.
These results suggest that the activation of PKC in the spinal cord may play an essential
role in the suppression of the morphine-induced rewarding effect in mice with
neuropathic pain through the constant release of P-endorphin.
In Chapter 4:
   I confirmed that sciatic nerve ligation suppressed a place preference induced by
DAMGO and reduced both the increase in the level of extracellular dopamine by s.c.
morphine in the nucleus accumbens and [35S]GTPyS binding to membranes of the VTA
induced by DAMGO. Interestingly, these effects were eliminated in mice that lacked
the P-endorphin gene. Furthermore, intra-VTA injection of a specific antibody to the
endogenous p-opioid peptideP-endorphin reversed the suppression of the
DAMGO-induced rewarding effect by sciatic nerve ligation in rats. These results
provide molecular evidence that nerve injury results in the continuous release of
endogenous P-endorphin and in turn the dysfunction of pt-opioid receptors in the VTA.
This phenomenon could explain the mechanism that underlies the suppression of opioid
reward under a neuropathic pain-like state (See Fig. A).
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